WO2022182968A1 - Synergistic compositions and methods to increase vascular nitric oxide to treat endothelial dysfunction and related conditions - Google Patents
Synergistic compositions and methods to increase vascular nitric oxide to treat endothelial dysfunction and related conditions Download PDFInfo
- Publication number
- WO2022182968A1 WO2022182968A1 PCT/US2022/017869 US2022017869W WO2022182968A1 WO 2022182968 A1 WO2022182968 A1 WO 2022182968A1 US 2022017869 W US2022017869 W US 2022017869W WO 2022182968 A1 WO2022182968 A1 WO 2022182968A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- precursor
- combinations
- oral dosage
- dosage form
- therapeutic composition
- Prior art date
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 436
- 239000000203 mixture Substances 0.000 title claims abstract description 169
- 206010048554 Endothelial dysfunction Diseases 0.000 title claims abstract description 49
- 230000008694 endothelial dysfunction Effects 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000002792 vascular Effects 0.000 title description 11
- 230000002195 synergetic effect Effects 0.000 title description 7
- 239000002243 precursor Substances 0.000 claims abstract description 167
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 88
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims abstract description 81
- 229920002306 Glycocalyx Polymers 0.000 claims abstract description 26
- 210000004517 glycocalyx Anatomy 0.000 claims abstract description 26
- 239000003937 drug carrier Substances 0.000 claims abstract description 19
- 230000003511 endothelial effect Effects 0.000 claims abstract description 18
- 230000006378 damage Effects 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 14
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 75
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 66
- 239000006186 oral dosage form Substances 0.000 claims description 63
- 239000003963 antioxidant agent Substances 0.000 claims description 53
- 235000006708 antioxidants Nutrition 0.000 claims description 48
- 230000003078 antioxidant effect Effects 0.000 claims description 47
- 229910002651 NO3 Inorganic materials 0.000 claims description 35
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 35
- 239000000284 extract Substances 0.000 claims description 31
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 20
- ZFAHNWWNDFHPOH-YFKPBYRVSA-N S-allylcysteine Chemical compound OC(=O)[C@@H](N)CSCC=C ZFAHNWWNDFHPOH-YFKPBYRVSA-N 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 15
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 15
- 229960004308 acetylcysteine Drugs 0.000 claims description 15
- 239000003755 preservative agent Substances 0.000 claims description 15
- 241000196324 Embryophyta Species 0.000 claims description 14
- 229960003180 glutathione Drugs 0.000 claims description 13
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 12
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 12
- 230000002335 preservative effect Effects 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 10
- 229940116229 borneol Drugs 0.000 claims description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 10
- 235000008434 ginseng Nutrition 0.000 claims description 10
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- ZFAHNWWNDFHPOH-UHFFFAOYSA-N S-Allyl-L-cystein Natural products OC(=O)C(N)CSCC=C ZFAHNWWNDFHPOH-UHFFFAOYSA-N 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
- 239000006172 buffering agent Substances 0.000 claims description 9
- 239000011777 magnesium Chemical class 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 9
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 239000012929 tonicity agent Substances 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 9
- 229910052725 zinc Inorganic materials 0.000 claims description 9
- 235000021537 Beetroot Nutrition 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000002270 dispersing agent Substances 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 150000002898 organic sulfur compounds Chemical class 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 244000024675 Eruca sativa Species 0.000 claims description 7
- 235000014755 Eruca sativa Nutrition 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 7
- 235000000183 arugula Nutrition 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 240000002234 Allium sativum Species 0.000 claims description 6
- 240000007087 Apium graveolens Species 0.000 claims description 6
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 6
- 235000010591 Appio Nutrition 0.000 claims description 6
- 240000007124 Brassica oleracea Species 0.000 claims description 6
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 6
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 6
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 6
- 102000016938 Catalase Human genes 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930064664 L-arginine Natural products 0.000 claims description 6
- 235000014852 L-arginine Nutrition 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 235000004611 garlic Nutrition 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- PGRNZHOQVAPMFX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N PGRNZHOQVAPMFX-WCCKRBBISA-N 0.000 claims description 5
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims description 5
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 5
- 240000006108 Allium ampeloprasum Species 0.000 claims description 5
- 241000304531 Allium macrostemon Species 0.000 claims description 5
- 235000007258 Anthriscus cerefolium Nutrition 0.000 claims description 5
- 240000002022 Anthriscus cerefolium Species 0.000 claims description 5
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 claims description 5
- 235000011332 Brassica juncea Nutrition 0.000 claims description 5
- 244000178993 Brassica juncea Species 0.000 claims description 5
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 claims description 5
- 235000021538 Chard Nutrition 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 5
- 244000298479 Cichorium intybus Species 0.000 claims description 5
- 241000723347 Cinnamomum Species 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 240000006927 Foeniculum vulgare Species 0.000 claims description 5
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 5
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 5
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 235000003228 Lactuca sativa Nutrition 0.000 claims description 5
- 240000008415 Lactuca sativa Species 0.000 claims description 5
- 235000007849 Lepidium sativum Nutrition 0.000 claims description 5
- 244000211187 Lepidium sativum Species 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 5
- 244000088415 Raphanus sativus Species 0.000 claims description 5
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 5
- 235000017276 Salvia Nutrition 0.000 claims description 5
- 240000007164 Salvia officinalis Species 0.000 claims description 5
- 239000009759 San-Chi Substances 0.000 claims description 5
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 5
- 244000300264 Spinacia oleracea Species 0.000 claims description 5
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims description 5
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 5
- 229960002173 citrulline Drugs 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 235000003969 glutathione Nutrition 0.000 claims description 5
- 229910001959 inorganic nitrate Inorganic materials 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 150000002540 isothiocyanates Chemical class 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 150000008116 organic polysulfides Chemical class 0.000 claims description 5
- 235000011197 perejil Nutrition 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 244000132619 red sage Species 0.000 claims description 5
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 108010053835 Catalase Proteins 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- NYRAVIYBIHCEGB-UHFFFAOYSA-N [K].[Ca] Chemical class [K].[Ca] NYRAVIYBIHCEGB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000090 biomarker Substances 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 150000002823 nitrates Chemical class 0.000 claims description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims description 4
- 229910052979 sodium sulfide Inorganic materials 0.000 claims description 4
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 3
- 235000019136 lipoic acid Nutrition 0.000 claims description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 3
- 235000005282 vitamin D3 Nutrition 0.000 claims description 3
- 239000011647 vitamin D3 Substances 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 229940021056 vitamin d3 Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 229920000855 Fucoidan Polymers 0.000 claims description 2
- 241000989762 Monostroma nitidum Species 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 229940102480 bilberry extract Drugs 0.000 claims description 2
- 235000019209 bilberry extract Nutrition 0.000 claims description 2
- 235000021466 carotenoid Nutrition 0.000 claims description 2
- 150000001747 carotenoids Chemical class 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- 238000001446 dark-field microscopy Methods 0.000 claims description 2
- 230000010339 dilation Effects 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims description 2
- 235000007672 methylcobalamin Nutrition 0.000 claims description 2
- 239000011585 methylcobalamin Substances 0.000 claims description 2
- 235000010333 potassium nitrate Nutrition 0.000 claims description 2
- 239000004323 potassium nitrate Substances 0.000 claims description 2
- 239000011677 pyridoxine Substances 0.000 claims description 2
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 229960004617 sapropterin Drugs 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 240000009164 Petroselinum crispum Species 0.000 claims 3
- 241000383638 Allium nigrum Species 0.000 claims 1
- 239000006000 Garlic extract Substances 0.000 claims 1
- 229930003451 Vitamin B1 Natural products 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 235000020706 garlic extract Nutrition 0.000 claims 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 description 57
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 17
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 17
- 239000003642 reactive oxygen metabolite Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000037361 pathway Effects 0.000 description 16
- 239000000463 material Substances 0.000 description 14
- 230000008753 endothelial function Effects 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 210000003038 endothelium Anatomy 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- -1 superoxide anions Chemical class 0.000 description 10
- 208000024172 Cardiovascular disease Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003855 balanced salt solution Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000002459 sustained effect Effects 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 229920002675 Polyoxyl Polymers 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 5
- 229960004860 thiamine mononitrate Drugs 0.000 description 5
- 235000019191 thiamine mononitrate Nutrition 0.000 description 5
- 239000011748 thiamine mononitrate Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- IHQDGXUYTSZGOG-UHFFFAOYSA-N Erucin Chemical compound CSCCCCN=C=S IHQDGXUYTSZGOG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000018927 edible plant Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Chemical class 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Chemical class 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000008108 microcrystalline cellulose Chemical class 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108030002440 Catalase peroxidases Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Chemical class 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Chemical class 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Chemical class 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 244000062780 Petroselinum sativum Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 241001593968 Vitis palmata Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 239000003911 antiadherent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000011575 calcium Chemical class 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Chemical class 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 235000013761 grape skin extract Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Chemical class 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000018537 nitric oxide storage Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000015487 sulforaphane Nutrition 0.000 description 2
- 229960005559 sulforaphane Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 230000006438 vascular health Effects 0.000 description 2
- 230000006442 vascular tone Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000001196 vasorelaxation Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- YTKBWWKAVMSYHE-OALUTQOASA-N (3s)-3-[3-(3-hydroxy-4-methoxyphenyl)propylamino]-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H](CC(O)=O)NCCCC=1C=C(O)C(OC)=CC=1)C1=CC=CC=C1 YTKBWWKAVMSYHE-OALUTQOASA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 239000004394 Advantame Substances 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 241000196222 Codium fragile Species 0.000 description 1
- 229920002261 Corn starch Chemical class 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000001387 Lonicera caerulea Nutrition 0.000 description 1
- 240000002734 Lonicera caerulea Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 244000132436 Myrica rubra Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 108010093901 N-(N-(3-(3-hydroxy-4-methoxyphenyl) propyl)-alpha-aspartyl)-L-phenylalanine 1-methyl ester Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 108010001742 S-Nitrosoglutathione Proteins 0.000 description 1
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 description 1
- 108010093594 S-nitrosoalbumin Proteins 0.000 description 1
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 1
- 108010068048 S-nitrosohemoglobin Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241001409321 Siraitia grosvenorii Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000019453 advantame Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000013949 black currant juice Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- QTDIPNAZPWHKMZ-UHFFFAOYSA-P calcium;2-[4,7-bis(carboxylatomethyl)-10-(2-oxidopropyl)-1,4,7,10-tetrazoniacyclododec-1-yl]acetate;hydron Chemical compound [H+].[Ca+2].CC([O-])C[NH+]1CC[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC1 QTDIPNAZPWHKMZ-UHFFFAOYSA-P 0.000 description 1
- 229960004858 calteridol Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000015120 cherry juice Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000020379 cucumber juice Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 108010014606 glutathione-bicarbonate-Ringer solution Proteins 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940096428 hawthorn berry Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000013187 longer-term treatment Methods 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940066429 octoxynol Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 235000013997 pineapple juice Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000013948 strawberry juice Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- AXFGWXLCWCNPHP-UHFFFAOYSA-N versetamide Chemical compound COCCNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCOC AXFGWXLCWCNPHP-UHFFFAOYSA-N 0.000 description 1
- 229960002569 versetamide Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Definitions
- ROS reactive oxygen species
- CVD cardiovascular diseases
- ROS reactive oxygen species
- phosphate nicotinamide adenine dinucleotide
- xanthine oxidase xanthine oxidase
- lipoxygenase mitochondria
- ROS may mediate various signaling pathways that underlie vascular inflammation in atherogenesis: from the initiation of fatty streak development through lesion progress to ultimate plaque rupture.
- FIG.1 is a graph of saliva NO2 over time in accordance with Example 1.
- FIG.2 is a graph of saliva NO2 over time in accordance with Example 2.
- FIG.3 is a graph of saliva NO 2 over time in accordance with Example 3.
- FIG.4 is a graph of saliva NO2 over time in accordance with Example 4.
- a method of treating endothelial dysfunction (ED) in a subject can optionally include identifying endothelial glycocalyx (EGX) and/or endothelial dysfunction of the subject.
- the method can further include administering to the subject a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount and at a frequency sufficient to restore and sustain an optimal NO level and endothelial function.
- a therapeutic composition for treating endothelial dysfunction can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H 2 S) precursor in an amount sufficient to treat endothelial dysfunction.
- a therapeutic composition for treating endothelial dysfunction can further include one or more antioxidants to deactivate superoxide and its downstream ROS to increase NO availability.
- a therapeutic composition for treating endothelial dysfunction can further include an endothelial glycocalyx regenerating compound (eGRC) to repair and restore EGX to support optimal NO synthesis by endothelial nitric oxide synthase (eNOS) and antioxidant defense against endothelial damage.
- eGRC endothelial glycocalyx regenerating compound
- eNOS endothelial nitric oxide synthase
- a therapeutic composition for treating endothelial dysfunction can further include one or more cofactors to optimize the production, transportation, storage and release of nitric oxide in the body.
- the therapeutic composition can further include a pharmaceutically acceptable carrier.
- An oral dosage form can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to sustain a long-lasting effect to treat endothelial dysfunction.
- the oral dosage form can further include a pharmaceutically acceptable carrier.
- substantially refers to a degree of deviation that is sufficiently small so as to not measurably detract from the identified property or circumstance. The exact degree of deviation allowable may in some cases depend on the specific context.
- adjacent refers to the proximity of two structures or elements. Particularly, elements that are identified as being “adjacent” may be either abutting or connected. Such elements may also be near or close to each other without necessarily contacting each other. The exact degree of proximity may in some cases depend on the specific context.
- the term “dosage unit” or “dose” are understood to mean an amount of an active agent that is suitable for administration to a subject in order achieve or otherwise contribute to a therapeutic effect.
- a dosage unit can refer to a single dose that is capable of being administered to a subject or patient, and that may be readily handled and packed, remaining as a physically and chemically stable unit dose.
- a “dosing regimen” or “regimen” such as “treatment dosing regimen,” or a “prophylactic dosing regimen” refers to how, when, how much, and for how long a dose of an active agent or composition can or should be administered to a subject in order to achieve an intended treatment or effect.
- the terms “treat,” “treatment,” or “treating” refers to administration of a therapeutic agent to subjects who are either asymptomatic or symptomatic.
- “treat,” “treatment,” or “treating” can be to reduce, ameliorate or eliminate symptoms associated with a condition present in a subject, or can be prophylactic, (i.e. to prevent or reduce the occurrence of the symptoms in a subject). Such prophylactic treatment can also be referred to as prevention of the condition.
- the terms “therapeutic agent,” “active agent,” and the like can be used interchangeably and refer to an agent that can have a beneficial or positive effect on a subject when administered to the subject in an appropriate or effective amount.
- an “effective amount,” “therapeutically effective amount,” or “therapeutically effective rate(s)” of an active ingredient refers to a substantially non-toxic, but sufficient amount or delivery rates of the active ingredient, to achieve therapeutic results in treating a disease or condition for which the drug is being delivered. It is understood that various biological factors may affect the ability of a substance to perform its intended task. Therefore, an “effective amount,” “therapeutically effective amount,” or “therapeutically effective rate(s)” may be dependent in some instances on such biological factors. Further, while the achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a subjective decision.
- formulation and composition can be used interchangeably and refer to a combination of at least two ingredients.
- at least one ingredient may be an active agent or otherwise have properties that exert physiologic activity when administered to a subject.
- amniotic fluid includes at least two ingredients (e.g. water and electrolytes) and is itself a composition or formulation.
- a “subject” refers to an animal. In one aspect the animal may be a mammal. In another aspect, the mammal may be a human.
- release and “release rate” are used interchangeably to refer to the discharge or liberation of a substance, including without limitation a drug, from the dosage form into a surrounding environment such as an aqueous medium either in vitro or in vivo.
- a substance including without limitation a drug
- release rate a substance that is released from the dosage form into a surrounding environment such as an aqueous medium either in vitro or in vivo.
- a plurality of items, structural elements, compositional elements, and/or materials may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.
- the term “at least one of” is intended to be synonymous with “one or more of.”
- “at least one of A, B and C” explicitly includes only A, only B, only C, and combinations of each.
- Concentrations, amounts, and other numerical data may be presented herein in a range format. It is to be understood that such range format is used merely for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub- range is explicitly recited.
- a numerical range of about 1 to about 4.5 should be interpreted to include not only the explicitly recited limits of 1 to about 4.5, but also to include individual numerals such as 2, 3, 4, and sub-ranges such as 1 to 3, 2 to 4, etc.
- the same principle applies to ranges reciting only one numerical value, such as “less than about 4.5,” which should be interpreted to include all of the above-recited values and ranges. Further, such an interpretation should apply regardless of the breadth of the range or the characteristic being described. Any steps recited in any method or process claims may be executed in any order and are not limited to the order presented in the claims.
- NO nitric oxide
- LDL low- density lipoprotein
- Endothelial cells include the enzyme endothelial nitric oxide synthase (eNOS) that produces NO from amino acid L-arginine in response to blood flow via the endogenous pathway.
- eNOS endothelial nitric oxide synthase
- the EGX is the mechanosensory and signal transducer of blood flow shear stress for eNOS.
- ED and a reduction in NO are implicated in numerous diseases and conditions. Aging can also lead to impaired endothelial function and a reduction of NO biosynthesis in the endothelium. Therefore, effective therapies are needed to address this issue.
- ROS reactive oxygen species
- mitochondrial enzymes xanthin oxidase, lipoxygenase, and NADPH oxidase
- NADPH reactive oxygen species
- One of the most damaging ROS of biological significance is superoxide anion (O2 ⁇ ) because of its capacity to generate other more reactive species.
- the superoxide anion can cause severe oxidative damage inside the body.
- the superoxide anion can react with NO to form peroxynitrite (ONOO-).
- O2 + NO ⁇ ONO 2 Peroxynitrite is a powerful oxidant that can damage a wide variety of molecules in cells, including lipids, DNA, and proteins.
- Biomarkers such as saliva NO 2 /NO 3 , breath NO and H 2 S, blood antioxidant markers, and also endothelial function can be used to monitor performance and EGX function.
- the vascular tissues have antioxidant systems that continuously operate to counterbalance the ROS generated.
- Some of these antioxidant systems include superoxide dismutase (SOD), catalase, thioredoxins (TRX) peroxidase, glutathione (GSH) peroxidase, and heme oxygenase.
- SOD superoxide dismutase
- TRX thioredoxins
- GSH glutathione
- heme oxygenase heme oxygenase.
- SOD superoxide dismutase
- SOD converts superoxide anions to hydrogen peroxide (H2O2) and oxygen.
- Hydrogen peroxide can be further reduced to water by other antioxidant enzymes (e.g., catalase and glutathione peroxidase).
- Catalase and glutathione peroxidase can stop hydrogen peroxide from reacting with ferrous ion to produce the hydroxyl radical.
- NO can also be derived from dietary nitrite and nitrate.
- a significant portion of systemic nitric oxide may be generated by reduction of nitrate to nitrite to nitric oxide by other enzymatic systems including the one that exists in the commensal gram-negative bacteria on the tongue.
- NO can play a role in maintaining endothelial health.
- the endogenous pathway can be aided by supplementation with L-arginine, L-arginine alpha-ketoglutarate, and L-citrulline.
- this approach might not be very effective or efficient in boosting NO biosynthesis.
- dietary intake of L-arginine is not a limiting factor for NO synthesis.
- the human body cannot maintain storage of excess amino acids; rather, the human body either uses them to synthesize proteins or break them down to produce energy.
- the eNOS enzyme can be reduced in quantity and/or activity with ED. Therefore, supplementation of substrates for eNOS via the endogenous pathway is not adequate.
- the exogenous pathway can be aided by using inorganic nitrite and nitrate to increase systemic NO.
- Targeting the exogenous pathway can be effective with a healthy oral microflora.
- oral supplementation of inorganic nitrite and nitrate increases the overall supply of NO in the circulation indiscriminately. This is in contrast to the endogenous pathway that produces NO at a specific location and time in response to blood flow. Since O2 ⁇ is also increased with ED, excess NO can react with O2 ⁇ to generate peroxynitrite, and result in an increase in oxidative stress. Therefore, supplementation via the exogenous pathway is not adequate either.
- compositions, dosage forms, and methods that can be used to increase vascular nitric oxide to treat endothelial dysfunction (ED) and related conditions.
- the compositions, dosage forms, and methods described herein can be used to reduce oxidative stress and also restore the EGX.
- each of these discussions can be considered applicable to each of these examples, whether or not they are explicitly discussed in the context of that example.
- such discussion also refers to the dosage forms and the methods described herein, and vice versa.
- This disclosure includes various ways of boosting NO by using the related activity between NO and hydrogen sulfide (H 2 S) – two gastro-transmitters that regulate each other to control vascular tone.
- H 2 S hydrogen sulfide
- H2 S work together with NO to regulate homeostasis of endothelial function via its vasorelaxing effects.
- H2S increases, potentiates, restores, spares, complements, and backs up NO production. It plays a compensatory role for the lack of NO production in the endothelial dysfunction.
- N-acetyl cysteine (NAC) and S-allyl cysteine (SAC) are antioxidants also known to increase hydrogen sulfide production inside the body via different mechanisms.
- One way that H2S interacts with NO and some NO precursors/donors is to generate S- nitrosothiols (SNOS).
- the small SNOS including S-nitrosocysteine and S- nitrosoglutathione can also transfer NO to other thiol containing molecules such as albumin and hemoglobin via transnitrosation to form S-nitrosoalbumin and S-nitrosohemoglobin.
- SNOS are widely present in the vascular system with important biological functions including storage, transport and release of NO.
- blood and saliva SNOS levels can be as important biomarkers as those of NO in assessing the NO status and endothelial function.
- This disclosure also presents synergistic interactions between the endogenous and exogenous pathways, and various ways of boosting antioxidation to prevent reactions between NO and O 2 ⁇ .
- This disclosure further includes ways of restoring endothelial function to enhance NO synthesis via eNOS by repairing, regenerating, and restoring the endothelial glycocalyx (EGX).
- the EGX is a micro-thin gel layer that coats the entire luminal surface of blood vessels, protects the endothelium from being damaged, and serves as a biomechanical sensor and signal transducer in blood vessels.
- the EGX can sense the shear stress of blood flow and send the signal to eNOS in the endothelial cell to produce NO.
- a healthy EGX can generate NO for various physiological functions.
- the EGX can also mediate and determine various endothelial functions.
- the EGX harbors many antioxidants including ecSOD that prevents superoxide to damage endothelium and reduce NO availability. Some factors that damage the endothelium can also damage the EGX. Endothelial function can be enhanced by restoring the EGX which can result in further synthesis of NO.
- O 2 ⁇ can be removed by using specific antioxidant enzymes, such as superoxide dismutase, catalase, or GSH peroxidase (which can target the downstream metabolite H 2 O 2 of superoxide dismutase).
- the EGX can also bind and harbor a variety of soluble molecules derived from both the endothelium and circulating blood that relate to the structural and functional properties of EGX.
- extracellular superoxide dismutase (ecSOD) can contribute to the antioxidant activities of the EGX to protect the EGX damage.
- O2 ⁇ can be removed by using specific nonenzymatic antioxidants including but not limited to glutathione (GSH), vitamin C and polyphenols/flavonoids.
- a therapeutic composition for treating endothelial dysfunction can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to sustain an increase of bioavailable NO for the treatment of endothelial dysfunction, and a pharmaceutically acceptable carrier.
- NO nitric oxide
- H2S hydrogen sulfide
- the NO precursor can be drawn from various sources, including the exogenous pathway or the endogenous pathway.
- the NO precursor when the NO precursor is drawn from the endogenous pathway, can include L-arginine, L-arginine alpha- ketoglutarate, L-citrulline, or combinations thereof.
- the NO precursor when the NO precursor is drawn from the exogenous pathway, can include inorganic nitrite, inorganic nitrate, organic nitrate, or combinations thereof.
- the NO precursor can include nitrite or nitrate salts of sodium, potassium calcium, magnesium, manganese, iron, copper, chromium, zinc, the like, or combinations thereof.
- the NO precursor, inorganic nitrite/nitrate can be derived from arugula, celery, cress, lettuce, chervil, beetroot, spinach, mustard greens, cabbage, fennel, leek, parsley, rocket, swiss chard, leafy chicory, Kohlrabi, radish, the like, or combinations thereof, by extraction, concentration, purification, and fermentation technologies.
- the NO precursor inorganic nitrite/nitrate
- the NO precursor can be an organic nitrate such as thiamine mononitrate. When the NO precursor is drawn from the exogenous pathway, the NO precursor can take various forms.
- the NO precursor can be a blend of powdered extracts. In another example, the NO precursor can be a blend of liquid extracts. In some examples, the NO precursor can be present in the therapeutic composition in a therapeutically effective amount. In some specific examples, the NO precursor can be present in the composition in an amount of from about 0.0001 wt% to about 80 wt%. In another example, the NO precursor can be present in the composition in an amount of from about 0.0001 wt% to about 40 wt%. In another example, the NO precursor can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%.
- the NO precursor can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%.
- inorganic nitrate of at least 30 mg, and in some cases 300-450 mg, can be effective.
- nitrite amounts of at least 3 mg can be effective.
- the H2S precursor can be drawn from various sources as well.
- the hydrogen sulfide precursor and stimulator can include sodium hydrosulfide (NaHS), sodium sulfide, N-acetyl cysteine (NAC), S-allyl cysteine (SAC), GSH, thiamine mononitrate, a garlic-derived organic polysulfide, a natural isothiocyanate from in the Brassicacease family such as erucin from arugula and sulforaphane from cruciferous vegetables, a sulfated oligosaccharide, a sulfated polysaccharide, any synthetic sulfur donor, the like, other organosulfur compounds (OSCs), synthetic H2S donors such as phosphorodithioate derivatives, NOSH compounds which act as both NO and H 2 S precursors, or combinations thereof.
- NaHS sodium hydrosulfide
- NaC N-acetyl cysteine
- SAC S-allyl cysteine
- GSH thiamine mononitrate
- the hydrogen sulfide precursor can be selected from a group consisting of: sodium hydrosulfide (NaHS), N-acetyl cysteine (NAC), S-allyl cysteine (SAC), GSH, thiamine mononitrate, a garlic-derived organic polysulfide, a natural isothiocyanate from in the Brassicacease family such as erucin from arugula and sulforaphane from cruciferous vegetables, any synthetic sulfur donor, the like, or combinations thereof.
- the H 2 S precursor can be substantially free of a sulfated oligosaccharide or a sulfated polysaccharide.
- the H 2 S precursor can be present in the therapeutic composition in a therapeutically effective amount. In some specific examples, the H2S precursor can be present in the composition in an amount of from about 0.0001 wt% to about 80 wt%. In another example, the H2S precursor can be present in the composition in an amount of from about 0.0001 wt% to about 90 wt%. In another example, the H 2 S precursor can be present in the composition in an amount of from about 0.0001 wt% to about 60 wt%. In another example, the H 2 S precursor can be present in the composition in an amount of from about 0.0001 wt% to about 30 wt%.
- the combination of the NO precursor and the H 2 S precursor can be present in an amount sufficient to treat endothelial dysfunction.
- the NO precursor and the H 2 S precursor can be present in amounts such that the ratio of amount (wt%) of NO precursor to amount (wt%) of H2S precursor is about 1:1.
- the NO precursor and the H2S precursor can be present in amounts such that the ratio of amount (wt%) of NO precursor to amount (wt%) of H2S precursor is from about 1:1 to about 1:10.
- the NO precursor and the H 2 S precursor can be present in amounts such that the ratio of amount (wt%) of NO precursor to amount (wt%) of H 2 S precursor is from about 10:1 to about 1:1.
- the therapeutic composition can also include an antioxidant.
- the antioxidant can include superoxide dismutase (SOD), catalase, glutathione peroxidase, the like, or combinations thereof.
- SOD superoxide dismutase
- the antioxidant can help inhibit oxidation of the nitric oxide precursor or hydrogen sulfide precursor or other ingredients in the therapeutic composition.
- the antioxidant can provide a therapeutic effect when administered in connection with the nitric oxide precursor or hydrogen sulfide precursor.
- a variety of antioxidants can be used in the therapeutic composition.
- the antioxidant can include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbic acid, ascorbyl palmitate, alpha tocopherol, potassium metabisulfite, sodium thiosulfate, propyl gallate, carotenoids, lipoic acid, ubiquinone, the like, or a combination thereof.
- the antioxidant can include a plant-based powder blend rich in antioxidants such as polyphenols.
- ROS oxidative stress and reactive oxygen species
- ROS can cause endothelial damage, progression of atherosclerosis, injury in sustained myocardial infarction and/or in ischemia reperfusion, the like, or a combination thereof.
- nitric oxide (NO) dependent vasorelaxation is a risk factor that can predispose individuals to cardiovascular disease.
- Plant-based antioxidants can also be used in the therapeutic composition.
- the antioxidants can be derived from red grape skin extract, red grape seed extract, white grape skin extract, white grape seed extract, green tea extract, carrot juice or extract, tomato juice or extract, broccoli juice or extract, green cabbage juice or extract, onion juice or extract, garlic juice or extract, asparagus juice or extract, olive juice or extract, cucumber juice or extract, bilberry juice or extract, grapefruit juice or extract, papaya juice or extract, pineapple juice or extract, strawberry juice or extract, apple juice or extract, apricot juice or extract, cherry juice or extract, orange juice or extract, black currant juice or extract, beetroot, (tartar) cherry, kiwi fruit, watermelon, hawthorn berry, celery, cili fruit, jujube fruit, broccoli, blue honeysuckle fruit, strawberry, yumberry, purple sweet potato
- the antioxidant can be present in the therapeutic composition in a variety of amounts. In some examples, the antioxidant can be present in the therapeutic composition in an amount sufficient to contribute to the antioxidant activity of the endothelial glycocalyx (EGX). In some examples, the antioxidant can be present in the therapeutic composition in a therapeutically effective amount. In some specific examples, the antioxidant can be present in the composition in an amount of from about 0.0001 wt% to about 90 wt%. In another example, the antioxidant can be present in the composition in an amount of from about 0.0001 wt% to about 30 wt%. In another example, the antioxidant can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%.
- EGX endothelial glycocalyx
- the antioxidant can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%. In some cases, the composition can be free of antioxidant.
- the therapeutic composition can also include an endothelial glycocalyx regenerator.
- the glycocalyx regenerator can include a sulfated polysaccharide, a sulfated oligosaccharide, chito-oligosaccharides (COS), other glycans and their precursors such as glucosamine, hyaluronan and chondroitin sulfate, or combinations thereof.
- the glycocalyx regenerator can include rhamnan sulfate, fucoidan sulfate, carrageenan, or combinations thereof.
- the glycocalyx regenerator can be present in the composition in an amount of from about 0.0001 wt% to about 80 wt%.
- the glycocalyx regenerator can be present in the composition in an amount of from about 0.0001 wt% to about 30 wt%.
- the glycocalyx regenerator can be present in the composition in an amount of from about 0.0001 wt% to about 20 wt%.
- the glycocalyx regenerator can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%. In some cases, the composition can be free of glycocalyx regenerator. In some other examples, the therapeutic composition can also include a source of nitrate and/or nitrite. Dietary nitrate and nitrite are precursors of nitric oxide (NO) that plays important roles in reducing reactive oxygen species.
- NO nitric oxide
- Nitric oxide is a vasodilator that increases blood flow. It also has anti-inflammatory, anticoagulant and antioxidant activities in relation to the development of atherosclerosis. It has been shown that dietary nitrate and nitrite lower blood pressure in humans.
- the therapeutic composition can include a variety of source of nitrate and nitrite.
- Non-limiting examples include thiamine mononitrate and nitrate and nitrite salts of sodium, potassium, calcium, magnesium, manganese, iron, copper, chromium and zinc. Also many fruits and vegetables are good sources of nitrate and nitrite.
- a non-exhausting list includes arugula, celery, cress, lettuce, chervil, beetroot, spinach, mustard greens, cabbage, fennel, leek, parsley, rocket, swiss chard, leafy chicory, Kohlrabi, radish, etc.
- Many herbs such as traditional Chinese medicinal herbs also contain an appreciable amount of nitrate and nitrite.
- the plant-based nitrate and nitrite can include a blend of powdered extracts. In still other examples, the plant-based nitrate and nitrite can include a blend of liquid extracts or juices.
- the nitrate and nitrite can be present in the therapeutic composition in an amount from about 10 wt% to about 90 wt%. In other examples, the nitrate and nitrite can be present in an amount from about 20 wt% to about 80 wt%.
- the therapeutic composition can include an NO precursor, an H 2 S precursor, and pharmaceutically acceptable carrier with one or more supplemental components such as an antioxidant, a glycocalyx regenerator, other cofactors supporting both endogenous and exogeneous NO pathways, and the like.
- optional additives can be added such as, but not limited to, sweeteners, colorants, flavorants, preservatives, and the like.
- the therapeutic composition can also include one or more factors that optimize the eNOS function and activity.
- suitable factors can include at least one of magnesium, zinc, pyridoxine (B6), folic acid (B9), vitamin B12, vitamin C, vitamin D, and tetrahydrobiopterin (BH4).
- the therapeutic composition can also include a pharmaceutically acceptable carrier. The nature of the pharmaceutically acceptable carrier can depend on the intended mode of administration.
- the therapeutic composition can be formulated for administration via injection.
- the therapeutic composition can be formulated for oral administration.
- the therapeutic composition can be formulated for IV administration.
- the pharmaceutically acceptable carrier can include one or more components suitable for such a composition.
- Non-limiting examples can include water, a solubilizing or dispersing agent, a tonicity agent, a pH adjuster or buffering agent, a preservative, a chelating agent, a bulking agent, the like, or a combination thereof.
- an injectable therapeutic composition can include a solubilizing or dispersing agent.
- Non-limiting examples of solubilizing or dispersing agents can include polyoxyethylene sorbitan monooleates, lecithin, polyoxyethylene polyoxypropylene co- polymers, propylene glycol, glycerin, ethanol, polyethylene glycols, sorbitol, dimethylacetamide, polyethoxylated castor oils, n-lactamide, cyclodextrins, caboxymethyl cellulose, acacia, gelatin, methyl cellulose, polyvinyl pyrrolidone, the like, or combinations thereof.
- an injectable therapeutic composition can include a tonicity agent.
- Non-limiting examples of tonicity agents can include sodium chloride, potassium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, dextrose, glycerin, propylene glycol, ethanol, trehalose, phosphate-buffered saline (PBS), Dulbecco’s PBS, Alsever’s solution, Tris-buffered saline (TBS), water, balanced salt solutions (BSS), such as Hank’s BSS, Earle’s BSS, Grey’s BSS, Puck’s BSS, Simm’s BSS, Tyrode’s BSS, and BSS Plus, the like, or combinations thereof.
- PBS phosphate-buffered saline
- TBS Tris-buffered saline
- BSS balanced salt solutions
- the tonicity agent can be used to provide an appropriate tonicity of the therapeutic composition.
- the tonicity of the therapeutic composition can be from about 250 to about 350 milliosmoles/liter (mOsm/L).
- the tonicity of the therapeutic composition can be from about 277 to about 310 mOsm/L.
- an injectable therapeutic composition can include a pH adjuster or buffering agent.
- Non-limiting examples of pH adjusters or buffering agents can include a number of acids, bases, and combinations thereof, such as hydrochloric acid, phosphoric acid, citric acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, acetate buffers, citrate buffers, tartrate buffers, phosphate buffers, triethanolamine (TRIS) buffers, the like, or combinations thereof.
- the pH of the therapeutic composition can be from about 5 to about 9, or from about 6 to about 8.
- an injectable therapeutic composition can include a preservative.
- Non-limiting examples of preservatives can include ascorbic acid, acetylcysteine, bisulfite, metabisulfite, monothioglycerol, phenol, meta-cresol, benzyl alcohol, methyl paraben, propyl paraben, butyl paraben, benzalkonium chloride, benzethonium chloride, butylated hydroxyl toluene, myristyl gamma-picolimium chloride, 2-phenoxyethanol, phenyl mercuric nitrate, chlorobutanol, thimerosal, tocopherols, the like, or combinations thereof.
- an injectable therapeutic composition can include a chelating agent.
- Non-limiting examples of chelating agents can include ethylenediaminetetra acetic acid, calcium, calcium disodium, versetamide, calteridol, diethylenetriaminepenta acetic acid, the like, or combinations thereof.
- an injectable therapeutic composition can include a bulking agent.
- Non-limiting examples of bulking agents can include sucrose, lactose, trehalose, mannitol, sorbitol, glucose, rafinose, glycine, histidine, polyvinyl pyrrolidone, the like, or combinations thereof.
- the pharmaceutically acceptable carrier can include one or more components suitable for such a composition.
- the pharmaceutically acceptable carrier can include a variety of components suitable for forming a capsule, tablet, or the like.
- the pharmaceutically acceptable carrier can include a variety of components suitable for forming a dispersion, a suspension, a syrup, an elixir, or the like.
- the therapeutic composition can be formulated as a tablet. In such examples, the therapeutic composition can typically include a binder.
- Non- limiting examples of binders can include lactose, calcium phosphate, sucrose, corn starch, microcrystalline cellulose, gelatin, polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP), hydroxypropyl cellulose, hydroxyethylcellulose, carboxymethyl cellulose (CMC), cellulose, other cellulose derivatives, the like, or combinations thereof.
- the therapeutic composition is formulated as a tablet, in some examples the therapeutic composition can also include a disintegrant.
- disintegrants can include crosslinked PVP, crosslinked CMC, modified starch, sodium starch glycolate, the like, or combinations thereof.
- the tablet can also include a filler.
- Non-limiting examples of fillers can include lactose, dicalcium phosphate, sucrose, microcrystalline cellulose, the like, or combinations thereof.
- the tablet can include a coating. Such coatings can be formed with a variety of materials, such as hydroxypropyl methylcellulose (HPMC), shellac, zein, various polysaccharides, various enterics, the like, or combinations thereof.
- the tablet can include a variety of other ingredients, such as anti- adherents (e.g. magnesium stearate, calcium stearate, for example), colorants (e.g. titanium dioxide, carmine, for example), glidants (e.g.
- the therapeutic composition can be formulated as a capsule.
- the capsule itself can typically include gelatin, hypromellose, HPMC, CMC, other plant-based capsule materials, the like, or combinations thereof.
- the therapeutic composition can be formulated as a liquid therapeutic composition or liquid oral dosage form.
- a liquid oral dosage form can include a variety of excipients, such as a liquid vehicle, a solubilizing agent, a thickener or dispersant, a preservative, a tonicity agent, a pH adjuster or buffering agent, a sweetener, a thickening agent, the like, or a combination thereof.
- Non-limiting examples of liquid vehicles can include water, ethanol, glycerol, propylene glycol, the like, or combinations thereof.
- Non-limiting examples of solubilizing agents can include banzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol-9, octoxynol, polyoxyethylene polyoxypropylene co-polymers, polyoxyl castor oils, polyoxyl hydrogenated castor oils, polyoxyl oleyl ethers, polyoxyl cetylstearyl ethers, polyoxyl stearates, polysorbates, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol, the like, or combinations thereof.
- Non-limiting examples of thickeners or dispersants can include sodium alginate, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, HPMC, CMC, microcrystalline cellulose, tragacanth, xanthan gum, bentonite, carrageenan, guar gum, colloidal silicon dioxide, the like, or combinations thereof.
- the preservative, tonicity agent, pH adjuster or buffering agent can typically be any of those described above with respect to the injectable formulations or other suitable preservative, tonicity agent, pH adjuster or buffering agent.
- Sweeteners can include natural and/or artificial sweeteners, such as sucrose, glucose, fructose, stevia, erythritol, xylitol, aspartame, sucralose, neotame, acesulfame potassium, saccharin, advantame, sorbitol, the like, or combinations thereof, for example.
- the therapeutic composition can be formulated as a functional food and/or medical food product such as a food bar, powder, or beverage. Food bars can be formulated to fit different dietary regiments for any specific purposes such as weight loss, energy, meal replacement, high protein, high fiber, low glycemic, etc.
- a food bar usually contains ingredients that supply energy-yielding nutrients such as carbohydrate, protein and lipid as well as other macro- and micronutrients including but not limited to vitamins and minerals.
- Other health promoting ingredients such fruit and vegetable powder may be included in the formulation in addition to filler, binder, emulsifier, water, humectant, flavor, color, sweetener, preservative, etc.
- the therapeutic composition can be formulated into a food bar with other ingredients to achieve desirable health benefits, taste, texture, flavor and stability.
- the therapeutic composition may be formulated into a powder such as a protein powder, meal replacement powder, or functional beverage dry mix. It can also be formulated into a functional drink.
- a ready to drink beverage may contain other ingredients including various nutrients, health promoting agents, pH adjustor (acidity regulator), electrolyte, flavor, sweetener, stabilizing agent, color, preservative, etc.
- the present disclosure also describes oral dosage forms.
- the oral dosage forms can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H 2 S) precursor in an amount sufficient to treat endothelial dysfunction.
- the oral dosage form can also include a pharmaceutically acceptable carrier.
- the types of NO precursors or hydrogen sulfide precursors that can be included in the oral dosage forms are generally described above with respect to the therapeutic compositions.
- the oral dosage form can include NO precursors or hydrogen sulfide precursors in an amount from about 0.5 mg to about 5,000 mg of NO precursors, hydrogen sulfide precursors, or both. In some other examples, the oral dosage form can include from about 5 mg to about 1500 mg of NO precursors, or hydrogen sulfide precursors, or both per dose. In some additional examples, the oral dosage form can include from about 10 mg to about 800 mg of NO precursors, or hydrogen sulfide precursors, or both per dose. In still other examples, the oral dosage form can include from about 50 mg to about 300 mg of NO precursors, or hydrogen sulfide precursors, or both per dose.
- the oral dosage forms can include an antioxidant, either antioxidant enzymes and/or nonenzymatic antioxidants, as described above with respect to the therapeutic compositions.
- the oral dosage form can include the plant antioxidant in an amount from about 20 mg to about 20,000 mg per dose.
- the antioxidant can be present in the oral dosage form in an amount from about 100 mg to about 600 mg per dose.
- the antioxidant can be present in the oral dosage form in an amount from about 125 mg to about 350 mg per dose.
- the antioxidant can be included in the oral dosage form in the form of a powdered blend of edible plant materials with antioxidant activity, such as those described above.
- the antioxidant can be included in the oral dosage form in the form of a liquid blend of edible plant materials with antioxidant activity, such as those described above.
- the oral dosage forms can include a source of nitrate and nitrite, as described above with respect to the therapeutic compositions.
- the oral dosage form can include nitrate and nitrite in an amount from about 20 mg to about 2,000 mg per dose.
- nitrate and nitrite can be present in the oral dosage form in an amount from about 50 mg to about 1,000 mg per dose.
- nitrate and nitrite can be present in the oral dosage form in an amount from about 200 mg to about 600 mg per dose.
- nitrate and nitrite can be included in the oral dosage form in the form of a powdered blend of edible plant materials with nitrate and nitrite, such as those described above.
- nitrate and nitrite can be included in the oral dosage form in the form of a liquid blend of edible plant materials with nitrate and nitrite, such as those described above.
- the oral dosage forms can be solid oral dosage forms. Where this is the case, the solid oral dosage forms can include any pharmaceutically acceptable carrier components suitable for a solid oral dosage form.
- the solid oral dosage form can include one or more of a binder, a disintegrant, a filler, an anti-adherent, a colorant, a glidant, a lubricant or anti-caking agent, a preservative, a desiccant, the like, or a combination thereof, such as those described above with respect to the therapeutic compositions.
- the solid oral dosage form can be formulated as a tablet.
- the solid oral dosage form can be formulated as a two-piece hard capsule or a hermetically sealed soft-gel capsule.
- the oral dosage forms can be liquid oral dosage forms.
- the liquid oral dosage forms can include any pharmaceutically acceptable carrier components suitable for a liquid oral dosage form.
- the liquid oral dosage form can include a liquid vehicle, a solubilizing agent, a thickener or dispersant, a preservative, a tonicity agent, a pH adjuster or buffering agent, a sweetener, the like, or a combination thereof, such as those described above.
- the dosage forms or therapeutic compositions described herein can be disposed in a suitable container.
- Such containers can include multiple-use containers or single use containers. Non-limiting examples can include bottles, vials, blister packs, bags, or the like.
- the container can be an amber colored container or other suitable container configured to protect the dosage form or therapeutic composition from light.
- the container can include instructions and dosing information for the dosage form or therapeutic composition.
- the container can include a variety of materials, such as polyethylene, polypropylene, polycarbonate, polyvinyl chloride, glass, the like, or a combination thereof.
- the therapeutic compositions described herein can be used as a food additive to fortify a food supply for general population.
- the therapeutic composition can be safely introduced into a systemic food supply such as, but not limited to, milled grain flours, pastas, breakfast cereals, bread, soup or soup mixes, food bars, spices, condiments, dairy products, beverages, drink mixes, frozen food items, pastries, cookies and crackers, snacks, or the like.
- a therapeutic composition can include two NO precursors, an H 2 S precursor, an endothelial glycocalyx regenerating compound, a nonenzymatic antioxidant, a plant-based antioxidant, and one or more eNOS cofactors.
- the two NO precursors can include potassium nitrate (100-500 mg/serving) and beetroot extract (50-2000 mg/serving)
- the H2S precursor can include SAC (100-1000 mg/serving) and thiamine mononitrate (1-100 mg/serving)
- the eGRC includes MNE (25-500 mg/serving)
- the nonenzymatic antioxidant includes Vitamin C (100-300 mg/serving)
- the plant-based antioxidant includes bilberry extract (50-500 mg/serving)
- the eNOS cofactors include magnesium (20-200 mg/serving), zinc (2-30 mg/serving), methyl cobalamin (10-200 mcg/serving), and cholecalciferol (10-200 mcg/serving).
- the present disclosure also describes a method of treating endothelial dysfunction.
- the method can include identifying endothelial glycocalyx (EGX) and/or endothelial dysfunction of the subject and administering to the subject a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount and at a frequency sufficient to stabilize and restore the EGX and endothelial function.
- NO nitric oxide
- H2S hydrogen sulfide
- damage in the EGX and endothelium can be detected using various blood markers, imaging technologies, and functional tests.
- biomarkers Alpha Elution Technology, dark field microscopy, coronary epicardial vasoactivity, flow-mediated dilation, plethysmography, and EndoPat may be used to assess EGX or endothelial dysfunction.
- Administration of the combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H 2 S) precursor to a subject can be performed in a number of ways.
- the combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor can be administered orally.
- Oral administration can include administration as a solid oral dosage form (e.g. a tablet, a capsule, etc.) or a liquid oral dosage form (e.g.
- administration can be performed via injection (e.g. intravenous, intra-arterial, intramuscular, sub-cutaneous, etc.). Further, where the composition is administered via injection, it can be injected via a bolus injection or via metered infusion. Other forms of administration can also include topical administration, transdermal administration, inhalation, ophthalmic administration, nasal administration, otic administration, administration as a suppository, or the like.
- the particular therapeutic composition administered can be any of those described herein, or the like.
- the combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H 2 S) precursor can be administered as a composition or dosage form, such as those described herein.
- the combination of the NO precursor and the H 2 S precursor can be administered in an amount from about 1 mg to about 15,000 mg per dose.
- the oral dosage form can be administered in an amount from about 10 mg to about 1500 mg of the combination of the NO precursor and the H2S precursor per dose.
- the oral dosage form can be administered in an amount from about 30 mg to about 300 mg of the combination of the NO precursor and the H2S precursor per dose.
- the oral dosage form can be administered in an amount from about 50 mg to about 200 mg of the combination of the NO precursor and the H2S precursor per dose. It is also noted that where the combination of the NO precursor and the H 2 S precursor is administered as part of a solid oral dosage form, a dose can include one, two, three, four, or more capsules, tablets, etc.
- the combination of the NO precursor and the H2S precursor can be administered at a variety of frequencies. In some examples, a dose of the combination of the NO precursor and the H2S precursor can be administered at a frequency of from once daily to four times daily.
- a dose of the combination of the NO precursor and the H 2 S precursor can be administered once per day, twice per day, three times per day, four times per day, or more.
- the combination of the NO precursor and the H 2 S precursor can be administered at a frequency of from about once every two days, three days, five days, or seven days, for example.
- a variety of suitable administration frequencies can be employed with the present methods.
- administration can continue for a variety of durations, depending on the desired treatment outcome.
- administration can continue while symptoms of ED persist.
- administration can be ongoing as either a prophylactic or intervention treatment.
- administration can continue until the ED has resolved or a threshold level of NO has been reached.
- administration duration can be from about 2 weeks to about 24 months, and often from 2 months to 12 months.
- the combination of the NO precursor and the H2S precursor can be administered in connection (e.g. co-administered) with another active agent.
- the second active agent can include an antioxidant, nitrate, nitrite, or a combination thereof, as described elsewhere herein.
- the present method takes advantage of synergistic mechanisms to generate and store NO which sustains a therapeutic level of NO in the vascular system beyond what can achieved by the existing approaches. Thus, the amount and frequency of therapeutic composition can be adjusted to achieve an increase of bioavailable NO for treatment of ED.
- such an increase can be sustained for a period of at least 12 hours, 24 hours, or 48 hours. In many examples, the increase can be sustained for at least 24 hours such that daily administration can be effective for longer term treatment and recovery. It is also noted that the present methods can be used to treat a number of adverse health conditions related to endothelial dysfunction.
- adverse health conditions can include coronary heart disease, myocardial infarction, carotid artery disease, stroke, peripheral artery disease, aneurysms, chronic kidney disease, erectile dysfunction, hypertension, Alzheimer’s disease, vascular dementia, diabetes, Raynaud’s disease, sleep apnea, the like, or a combination thereof.
- Example 1 – A Basic NO Precursor Composition (Formula 1) A basic NO Precursor containing composition was prepared by using the components set forth in Table I. The composition was prepared by weighing all of the components into a clean stainless-steel container and combining in a substantially inert environment to form a solution. A predetermined quantity of the fill material was disposed into a hard capsule to get the target NO precursor dose per dosage unit. The capsules were allowed to cool at room temperature, banded (if required) and packaged in a HDPE bottle and tightly closed with an appropriate lid.
- a predetermined quantity of the fill material was disposed into a capsule to get the target H2S precursor dose per dosage unit.
- the capsules were allowed to cool at room temperature, banded (if required) and packaged in a HDPE bottle and tightly closed with an appropriate lid.
- the composition was evaluated for its ability to increase NO production and availability.
- saliva nitrite after ingesting Formula 2 (dotted line) was higher than the baseline (solid line) at every time point ( Figure 2).
- saliva nitrite after ingesting Formula 2 was higher than that after ingesting Formula 1 (dashed Line) for 4 of the 7 time points (from 2 hours to 8 hours). It is worth noting the starting saliva nitrite was higher at 7.5 mg/L for Composition 1 than 5 mg/L for Formula 2.
- eGRC endothelial glycocalyx regenerating compound
- MNE Green seaweed Monostroma nitidum extract
- the composition was evaluated for its ability to increase NO production and availability.
- all data points of saliva nitrite for Formula 3 (dotted line) were higher than those of baseline (solid line).
- 3 of 7 data points (2, 4 and 8 hour) of Formula 3 are higher than those of Formula 1 (dashed line).
- the starting saliva nitrite was higher at 7.5 mg/L for Formula 1 than 5 mg/L for Formula 3.
- Formula 4 also includes additional plant polyphenols and vitamin D3, both increase eNOS activity and NO bioavailability.
- This formula actually contains less NO precursor and less H2S precursor than Formula 3. However, it was expected to work better due to the synergistic effect of its components.
- the composition was prepared by weighing all of the components into a clean stainless-steel container and combining in a substantially inert environment to form a solution. The composition was packaged and stored in a container. TABLE V (Formula 4) The composition was evaluated for its ability to increase NO bioavailability. A healthy young male ingested a single dose of the composition in the morning only.
- Table VII below presents the data on saliva SNOS. There was essentially no detectable SNOS before ingesting Formula 4. After Formula 4, saliva SNOS jumped to 80 mg/L in 2 hours and stayed higher for 12 hours. At the 12 hours, saliva SNOS was still much higher than the baseline. These data support the conclusion that H2S precursor stimulates H 2 S production inside the body. It also leads to a dramatic increase of NO storage inside the body which helps sustain an increased NO bioavailability for more than 12 hours.
- the waveform pattern can be used to assess the endothelial function and CVD risk.
- Table X lists the waveform types and corresponding vascular health conditions.
- Table X (Waveform Pattern) PWA shows the subject had suboptimal circulation and vessel condition with waveform type 4 (Table XI). After ingesting a single serving of Formula 4, the waveform improved in 2 hours. The beneficial effect lasted for 24 hours. This is not surprising and confirmed that Formula 4 sustained an increased NO bioavailability for 24 hours.
- TABLE XI (APG Waveform) Furthermore, a small human study was completed with 5 uncontrolled hypertensive patients at a research medical clinic. Each subject took a single serving of Formula 4 once in the morning every day for 2 weeks.
- Example 5 An Advanced NO Precursor with H 2 S Precursor Composition with an eGRC (Formula 5)
- the composition was prepared using the components set forth in Table XV (Formula 5), by adding the eGRC MNE in the composition of Example 4.
- MNE repairs, regenerates and restores the endothelial glycocalyx (EGX).
- EGX endothelial glycocalyx
- a healthy and optimal EGX enables eNOS to synthesize NO. It also houses extracellular superoxide dismutase (exSOD). exSOD that controls oxidative stress by ROS at the endothelium and makes more NO available for its biological function.
- Formula 5 has the advantage of additional synergistic effects to boost NO production and availability.
- Formula 5 will sustain a higher NO bioavailability for at least 24 hours especially with repeated single daily dosing for 2 weeks.
- the data indicate Formula 5 is even better than Formula 4 as an innovative therapeutic composition to increase vascular NO for the treatment of ED and related condition such as hypertension.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method of treating endothelial dysfunction in a subject can include: identifying damage in an endothelial glycocalyx (EGX) of the subject, and administering to the subject a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount and at a frequency sufficient to stabilize and reverse damage in the EGX. A therapeutic composition for treating endothelial dysfunction can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to sustain an increase of bioavailable NO for the treatment of endothelial dysfunction, and a pharmaceutically acceptable carrier.
Description
PATENT APPLICATION of Applicant: Calroy Health Sciences, LLC Inventors: Chen Chen Edward Hoyt Kevin Chen And Derek Chen for SYNERGISTIC COMPOSITIONS AND METHODS TO INCREASE VASCULAR NITRIC OXIDE TO TREAT ENDOTHELIAL DYSFUNCTION AND RELATED CONDITIONS THORPE NORTH & WESTERN, LLP ATTORNEYS AT LAW 8180 SOUTH 700 EAST, SUITE 350, SANDY, UTAH 84070 801.566.6633 TELEPHONE 801.566.0750 FACSIMILE
SYNERGISTIC COMPOSITIONS AND METHODS TO INCREASE VASCULAR NITRIC OXIDE TO TREAT ENDOTHELIAL DYSFUNCTION AND RELATED CONDITIONS RELATED APPLICATION This application claims priority to U.S. Provisional Patent Application No. 63/153,867, filed February 25, 2021 which is incorporated herein by reference. BACKGROUND Overproduction of reactive oxygen species (ROS) under pathophysiologic conditions may be involved in the development of cardiovascular diseases (CVD). These ROS can be released from nicotinamide adenine dinucleotide (phosphate) oxidase, xanthine oxidase, lipoxygenase, mitochondria, or the uncoupling of nitric oxide synthase in vascular cells. ROS may mediate various signaling pathways that underlie vascular inflammation in atherogenesis: from the initiation of fatty streak development through lesion progress to ultimate plaque rupture. Various animal models of oxidative stress support the notion that ROS is involved in atherosclerosis and other cardiovascular diseases, and some human investigations also support the oxidative stress hypothesis of atherosclerosis. Endothelial dysfunction (ED) is at the center of CVD. Many risk factors of heart disease cause damage to the endothelium and lead to ED. The common mechanism behind the endothelial damage is oxidative stress and the resulting inflammation and immune response. When damaged, the endothelium losses its capacity to produce nitric oxide (NO). The reduction of vascular NO leads to a further increase of oxidative stress in the system. This vicious cycle and the resulting loss of homeostatic balance between NO and ROS are the fundamental cause of ED. Many biological pathways and processes are involved in the control and metabolism of NO and ROS inside the body. Various products are available to target some of them separately. BRIEF DESCRIPTION OF THE DRAWINGS Features and advantages of the invention will be apparent from the detailed description that follows, and which taken in conjunction with the accompanying figures together illustrate features of the invention. It is understood that the figures merely depict exemplary embodiments and are therefore, not to be considered limiting in scope.
FIG.1 is a graph of saliva NO2 over time in accordance with Example 1. FIG.2 is a graph of saliva NO2 over time in accordance with Example 2. FIG.3 is a graph of saliva NO2 over time in accordance with Example 3. FIG.4 is a graph of saliva NO2 over time in accordance with Example 4. SUMMARY A method of treating endothelial dysfunction (ED) in a subject can optionally include identifying endothelial glycocalyx (EGX) and/or endothelial dysfunction of the subject. The method can further include administering to the subject a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount and at a frequency sufficient to restore and sustain an optimal NO level and endothelial function. A therapeutic composition for treating endothelial dysfunction can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to treat endothelial dysfunction. A therapeutic composition for treating endothelial dysfunction can further include one or more antioxidants to deactivate superoxide and its downstream ROS to increase NO availability. A therapeutic composition for treating endothelial dysfunction can further include an endothelial glycocalyx regenerating compound (eGRC) to repair and restore EGX to support optimal NO synthesis by endothelial nitric oxide synthase (eNOS) and antioxidant defense against endothelial damage. A therapeutic composition for treating endothelial dysfunction can further include one or more cofactors to optimize the production, transportation, storage and release of nitric oxide in the body. The therapeutic composition can further include a pharmaceutically acceptable carrier. An oral dosage form can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to sustain a long-lasting effect to treat endothelial dysfunction. The oral dosage form can further include a pharmaceutically acceptable carrier. There has thus been outlined, rather broadly, the more important features of the invention so that the detailed description thereof that follows may be better understood, and so that the present contribution to the art may be better appreciated. Other features of the present invention will become clearer from the following detailed description of the
invention, taken with the accompanying drawings and claims, or may be learned by the practice of the invention. DETAILED DESCRIPTION While these exemplary embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, it should be understood that other embodiments may be realized and that various changes to the invention may be made without departing from the spirit and scope of the present invention. Thus, the following more detailed description of the embodiments of the present invention is not intended to limit the scope of the invention, as claimed, but is presented for purposes of illustration only and not limitation to describe the features and characteristics of the present invention, to set forth the best mode of operation of the invention, and to sufficiently enable one skilled in the art to practice the invention. Accordingly, the scope of the present invention is to be defined solely by the appended claims. Definitions In describing and claiming the present invention, the following terminology will be used. The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cofactor” includes reference to one or more of such materials and reference to “subjecting” refers to one or more such steps. As used herein, the term “about” is used to provide flexibility and imprecision associated with a given term, metric or value. The degree of flexibility for a particular variable can be readily determined by one skilled in the art. However, unless otherwise enunciated, the term “about” generally connotes flexibility of less than 2%, and most often less than 1%, and in some cases less than 0.01%. As used herein with respect to an identified property or circumstance, “substantially” refers to a degree of deviation that is sufficiently small so as to not measurably detract from the identified property or circumstance. The exact degree of deviation allowable may in some cases depend on the specific context. As used herein, “adjacent” refers to the proximity of two structures or elements. Particularly, elements that are identified as being “adjacent” may be either abutting or connected. Such elements may also be near or close to each other without necessarily
contacting each other. The exact degree of proximity may in some cases depend on the specific context. The term “dosage unit” or “dose” are understood to mean an amount of an active agent that is suitable for administration to a subject in order achieve or otherwise contribute to a therapeutic effect. In some examples, a dosage unit can refer to a single dose that is capable of being administered to a subject or patient, and that may be readily handled and packed, remaining as a physically and chemically stable unit dose. As used herein, a “dosing regimen” or “regimen” such as “treatment dosing regimen,” or a “prophylactic dosing regimen” refers to how, when, how much, and for how long a dose of an active agent or composition can or should be administered to a subject in order to achieve an intended treatment or effect. As used herein, the terms “treat,” “treatment,” or “treating” refers to administration of a therapeutic agent to subjects who are either asymptomatic or symptomatic. In other words, “treat,” “treatment,” or “treating” can be to reduce, ameliorate or eliminate symptoms associated with a condition present in a subject, or can be prophylactic, (i.e. to prevent or reduce the occurrence of the symptoms in a subject). Such prophylactic treatment can also be referred to as prevention of the condition. As used herein, the terms “therapeutic agent,” “active agent,” and the like can be used interchangeably and refer to an agent that can have a beneficial or positive effect on a subject when administered to the subject in an appropriate or effective amount. The phrase “effective amount,” “therapeutically effective amount,” or “therapeutically effective rate(s)” of an active ingredient refers to a substantially non-toxic, but sufficient amount or delivery rates of the active ingredient, to achieve therapeutic results in treating a disease or condition for which the drug is being delivered. It is understood that various biological factors may affect the ability of a substance to perform its intended task. Therefore, an “effective amount,” “therapeutically effective amount,” or “therapeutically effective rate(s)” may be dependent in some instances on such biological factors. Further, while the achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a subjective decision. The determination of a therapeutically effective amount or delivery rate is well within the ordinary skill in the art of pharmaceutical sciences and medicine.
As used herein, formulation and composition can be used interchangeably and refer to a combination of at least two ingredients. In some embodiments, at least one ingredient may be an active agent or otherwise have properties that exert physiologic activity when administered to a subject. For example, amniotic fluid includes at least two ingredients (e.g. water and electrolytes) and is itself a composition or formulation. As used herein, a “subject” refers to an animal. In one aspect the animal may be a mammal. In another aspect, the mammal may be a human. As used herein, the terms “release” and “release rate” are used interchangeably to refer to the discharge or liberation of a substance, including without limitation a drug, from the dosage form into a surrounding environment such as an aqueous medium either in vitro or in vivo. As used herein, a plurality of items, structural elements, compositional elements, and/or materials may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary. As used herein, the term “at least one of” is intended to be synonymous with “one or more of.” For example, “at least one of A, B and C” explicitly includes only A, only B, only C, and combinations of each. Concentrations, amounts, and other numerical data may be presented herein in a range format. It is to be understood that such range format is used merely for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub- range is explicitly recited. For example, a numerical range of about 1 to about 4.5 should be interpreted to include not only the explicitly recited limits of 1 to about 4.5, but also to include individual numerals such as 2, 3, 4, and sub-ranges such as 1 to 3, 2 to 4, etc. The same principle applies to ranges reciting only one numerical value, such as “less than about 4.5,” which should be interpreted to include all of the above-recited values and ranges. Further, such an interpretation should apply regardless of the breadth of the range or the characteristic being described.
Any steps recited in any method or process claims may be executed in any order and are not limited to the order presented in the claims. Means-plus-function or step-plus- function limitations will only be employed where for a specific claim limitation all of the following conditions are present in that limitation: a) “means for” or “step for” is expressly recited; and b) a corresponding function is expressly recited. The structure, material or acts that support the means-plus function are expressly recited in the description herein. Accordingly, the scope of the invention should be determined solely by the appended claims and their legal equivalents, rather than by the descriptions and examples given herein. Compositions and Methods for Treatment of Endothelial Dysfunction Many vascular diseases result from oxidative stress that targets the endothelium, which can lead to inflammatory and immune responses that can result in endothelial activation and dysfunction. One of the major consequences of endothelial dysfunction (ED) is an impaired biosynthesis of nitric oxide (NO). NO is a vascular signaling molecule that is involved in the homeostasis of the vascular system. NO is also a vasodilator that maintains response to blood flow in blood vessels. NO can also reduce oxidation of low- density lipoprotein (LDL) to reduce platelet reactivity and decrease leukocyte stickiness in order to protect the vasculature. Consequently, defects in NO release due to endothelial dysfunction can induce vasoconstriction, pro-coagulability, and arterial stiffness. Endothelial cells include the enzyme endothelial nitric oxide synthase (eNOS) that produces NO from amino acid L-arginine in response to blood flow via the endogenous pathway. The EGX is the mechanosensory and signal transducer of blood flow shear stress for eNOS. ED (and a reduction in NO) are implicated in numerous diseases and conditions. Aging can also lead to impaired endothelial function and a reduction of NO biosynthesis in the endothelium. Therefore, effective therapies are needed to address this issue. The human body constantly generates reactive oxygen species (ROS) via various enzyme systems including mitochondrial enzymes, xanthin oxidase, lipoxygenase, and NADPH oxidase in the endothelium, smooth muscle cells, and adventitia of blood vessels. One of the most damaging ROS of biological significance is superoxide anion (O2−) because of its capacity to generate other more reactive species. The superoxide anion can cause severe oxidative damage inside the body. In one example, the superoxide anion can react with NO to form peroxynitrite (ONOO-).
O2 + NO → ONO 2 Peroxynitrite is a powerful oxidant that can damage a wide variety of molecules in cells, including lipids, DNA, and proteins. In fact, this is one of the mechanisms that the immune system uses to kill invading microorganisms. For example, activated macrophages produce NO as an innate immune response to invading pathogens. Oxidative stress and endothelial dysfunction can induce uncoupling of eNOS, resulting in the generation of O2 − instead of NO. In fact, superoxide itself can directly uncouple eNOS to produce more superoxide, a vicious cycle with devastating consequence to NO production and endothelial function. Therefore, the presence of excess NO and O2 − at the same place and the same time is detrimental to vascular health. Biomarkers such as saliva NO2/NO3, breath NO and H2S, blood antioxidant markers, and also endothelial function can be used to monitor performance and EGX function. On the other hand, the vascular tissues have antioxidant systems that continuously operate to counterbalance the ROS generated. Some of these antioxidant systems include superoxide dismutase (SOD), catalase, thioredoxins (TRX) peroxidase, glutathione (GSH) peroxidase, and heme oxygenase. Superoxide dismutase is an important antioxidant enzyme that protects from oxidative damage by superoxide radicals. Specifically, SOD converts superoxide anions to hydrogen peroxide (H2O2) and oxygen. Hydrogen peroxide can be further reduced to water by other antioxidant enzymes (e.g., catalase and glutathione peroxidase). 2O2 − + 2H+ ↔ H2O2 + O2 Catalase and glutathione peroxidase can stop hydrogen peroxide from reacting with ferrous ion to produce the hydroxyl radical. In addition to the endogenous pathway, NO can also be derived from dietary nitrite and nitrate. A significant portion of systemic nitric oxide may be generated by reduction of nitrate to nitrite to nitric oxide by other enzymatic systems including the one that exists in the commensal gram-negative bacteria on the tongue. Because of the prevalence of ED and related diseases and condition, NO can play a role in maintaining endothelial health. In some examples, the endogenous pathway can be aided by supplementation with L-arginine, L-arginine alpha-ketoglutarate, and L-citrulline.
However, this approach might not be very effective or efficient in boosting NO biosynthesis. In North America, dietary intake of L-arginine is not a limiting factor for NO synthesis. The human body cannot maintain storage of excess amino acids; rather, the human body either uses them to synthesize proteins or break them down to produce energy. Also, the eNOS enzyme can be reduced in quantity and/or activity with ED. Therefore, supplementation of substrates for eNOS via the endogenous pathway is not adequate. In other examples, the exogenous pathway can be aided by using inorganic nitrite and nitrate to increase systemic NO. Targeting the exogenous pathway can be effective with a healthy oral microflora. However, oral supplementation of inorganic nitrite and nitrate increases the overall supply of NO in the circulation indiscriminately. This is in contrast to the endogenous pathway that produces NO at a specific location and time in response to blood flow. Since O2− is also increased with ED, excess NO can react with O2− to generate peroxynitrite, and result in an increase in oxidative stress. Therefore, supplementation via the exogenous pathway is not adequate either. The present disclosure describes a number of compositions, dosage forms, and methods that can be used to increase vascular nitric oxide to treat endothelial dysfunction (ED) and related conditions. In some examples, the compositions, dosage forms, and methods described herein can be used to reduce oxidative stress and also restore the EGX. As a further note, in the present disclosure, it is noted that when discussing the compositions, the dosage forms, and the methods, each of these discussions can be considered applicable to each of these examples, whether or not they are explicitly discussed in the context of that example. Thus, for example, in discussing details about the compositions per se, such discussion also refers to the dosage forms and the methods described herein, and vice versa. This disclosure includes various ways of boosting NO by using the related activity between NO and hydrogen sulfide (H2S) – two gastro-transmitters that regulate each other to control vascular tone. While NO is undoubtedly the primary mediator in controlling vascular tone in health and disease, H2S work together with NO to regulate homeostasis of endothelial function via its vasorelaxing effects. H2S increases, potentiates, restores, spares, complements, and backs up NO production. It plays a compensatory role for the lack of NO production in the endothelial dysfunction. For example, hydrogen sulfide precursors N-acetyl cysteine (NAC) and S-allyl cysteine (SAC) are antioxidants also known to increase hydrogen sulfide production inside the body via different mechanisms.
One way that H2S interacts with NO and some NO precursors/donors is to generate S- nitrosothiols (SNOS). The small SNOS including S-nitrosocysteine and S- nitrosoglutathione can also transfer NO to other thiol containing molecules such as albumin and hemoglobin via transnitrosation to form S-nitrosoalbumin and S-nitrosohemoglobin. SNOS are widely present in the vascular system with important biological functions including storage, transport and release of NO. Therefore, blood and saliva SNOS levels can be as important biomarkers as those of NO in assessing the NO status and endothelial function. This disclosure also presents synergistic interactions between the endogenous and exogenous pathways, and various ways of boosting antioxidation to prevent reactions between NO and O2 −. This disclosure further includes ways of restoring endothelial function to enhance NO synthesis via eNOS by repairing, regenerating, and restoring the endothelial glycocalyx (EGX). The EGX is a micro-thin gel layer that coats the entire luminal surface of blood vessels, protects the endothelium from being damaged, and serves as a biomechanical sensor and signal transducer in blood vessels. The EGX can sense the shear stress of blood flow and send the signal to eNOS in the endothelial cell to produce NO. A healthy EGX can generate NO for various physiological functions. The EGX can also mediate and determine various endothelial functions. For example, the EGX harbors many antioxidants including ecSOD that prevents superoxide to damage endothelium and reduce NO availability. Some factors that damage the endothelium can also damage the EGX. Endothelial function can be enhanced by restoring the EGX which can result in further synthesis of NO. In some cases, O2 − can be removed by using specific antioxidant enzymes, such as superoxide dismutase, catalase, or GSH peroxidase (which can target the downstream metabolite H2O2 of superoxide dismutase). The EGX can also bind and harbor a variety of soluble molecules derived from both the endothelium and circulating blood that relate to the structural and functional properties of EGX. For example, extracellular superoxide dismutase (ecSOD) can contribute to the antioxidant activities of the EGX to protect the EGX damage. In other case, O2− can be removed by using specific nonenzymatic antioxidants including but not limited to glutathione (GSH), vitamin C and polyphenols/flavonoids. These antioxidants plus lipoic acid, beta carotene, vitamin E, and ubiquinone are also
effective against downstream ROS generated from superoxide including hydrogen peroxide, hydroxyl radical, peroxynitrite, and lipid peroxides. In further detail, a therapeutic composition for treating endothelial dysfunction can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to sustain an increase of bioavailable NO for the treatment of endothelial dysfunction, and a pharmaceutically acceptable carrier. The NO precursor can be drawn from various sources, including the exogenous pathway or the endogenous pathway. When the NO precursor is drawn from the endogenous pathway, the NO precursor can include L-arginine, L-arginine alpha- ketoglutarate, L-citrulline, or combinations thereof. When the NO precursor is drawn from the exogenous pathway, the NO precursor can include inorganic nitrite, inorganic nitrate, organic nitrate, or combinations thereof. In one example, the NO precursor can include nitrite or nitrate salts of sodium, potassium calcium, magnesium, manganese, iron, copper, chromium, zinc, the like, or combinations thereof. In another example, the NO precursor, inorganic nitrite/nitrate, can be derived from arugula, celery, cress, lettuce, chervil, beetroot, spinach, mustard greens, cabbage, fennel, leek, parsley, rocket, swiss chard, leafy chicory, Kohlrabi, radish, the like, or combinations thereof, by extraction, concentration, purification, and fermentation technologies. In another example, the NO precursor, inorganic nitrite/nitrate, can be derived from danshen root (Radix salvia miltorrhizae), snakegourd fruit (Fructus trichosanthis), longstamen onion bulb (Bulbus allii macrostemi), sanchi (Radix notoginseng), ginseng (Radix ginseng), borneol (Borneolum syntheticum), and borneol (Cinnamomum), or combinations thereof, by extraction, concentration, purification, and fermentation technologies. Yet in another example, the NO precursor can be an organic nitrate such as thiamine mononitrate. When the NO precursor is drawn from the exogenous pathway, the NO precursor can take various forms. In one example, the NO precursor can be a blend of powdered extracts. In another example, the NO precursor can be a blend of liquid extracts. In some examples, the NO precursor can be present in the therapeutic composition in a therapeutically effective amount. In some specific examples, the NO precursor can be present in the composition in an amount of from about 0.0001 wt% to about 80 wt%. In another example, the NO precursor can be present in the composition in an amount of from about 0.0001 wt% to about 40 wt%. In another example, the NO precursor can be present
in the composition in an amount of from about 0.0001 wt% to about 10 wt%. In another example, the NO precursor can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%. As a non-limiting example, inorganic nitrate of at least 30 mg, and in some cases 300-450 mg, can be effective. Similarly, for nitrite amounts of at least 3 mg can be effective. The H2S precursor can be drawn from various sources as well. In one example, the hydrogen sulfide precursor and stimulator can include sodium hydrosulfide (NaHS), sodium sulfide, N-acetyl cysteine (NAC), S-allyl cysteine (SAC), GSH, thiamine mononitrate, a garlic-derived organic polysulfide, a natural isothiocyanate from in the Brassicacease family such as erucin from arugula and sulforaphane from cruciferous vegetables, a sulfated oligosaccharide, a sulfated polysaccharide, any synthetic sulfur donor, the like, other organosulfur compounds (OSCs), synthetic H2S donors such as phosphorodithioate derivatives, NOSH compounds which act as both NO and H2S precursors, or combinations thereof. In another example, the hydrogen sulfide precursor can be selected from a group consisting of: sodium hydrosulfide (NaHS), N-acetyl cysteine (NAC), S-allyl cysteine (SAC), GSH, thiamine mononitrate, a garlic-derived organic polysulfide, a natural isothiocyanate from in the Brassicacease family such as erucin from arugula and sulforaphane from cruciferous vegetables, any synthetic sulfur donor, the like, or combinations thereof. In one example, the H2S precursor can be substantially free of a sulfated oligosaccharide or a sulfated polysaccharide. In some examples, the H2S precursor can be present in the therapeutic composition in a therapeutically effective amount. In some specific examples, the H2S precursor can be present in the composition in an amount of from about 0.0001 wt% to about 80 wt%. In another example, the H2S precursor can be present in the composition in an amount of from about 0.0001 wt% to about 90 wt%. In another example, the H2S precursor can be present in the composition in an amount of from about 0.0001 wt% to about 60 wt%. In another example, the H2S precursor can be present in the composition in an amount of from about 0.0001 wt% to about 30 wt%. In some further examples, the combination of the NO precursor and the H2S precursor can be present in an amount sufficient to treat endothelial dysfunction. In one example, the NO precursor and the H2S precursor can be present in amounts such that the ratio of amount (wt%) of NO precursor to amount (wt%) of H2S precursor is about 1:1. In
another example, the NO precursor and the H2S precursor can be present in amounts such that the ratio of amount (wt%) of NO precursor to amount (wt%) of H2S precursor is from about 1:1 to about 1:10. In another example, the NO precursor and the H2S precursor can be present in amounts such that the ratio of amount (wt%) of NO precursor to amount (wt%) of H2S precursor is from about 10:1 to about 1:1. In some further examples, the therapeutic composition can also include an antioxidant. In one example, the antioxidant can include superoxide dismutase (SOD), catalase, glutathione peroxidase, the like, or combinations thereof. In some cases, the antioxidant can help inhibit oxidation of the nitric oxide precursor or hydrogen sulfide precursor or other ingredients in the therapeutic composition. In some examples, the antioxidant can provide a therapeutic effect when administered in connection with the nitric oxide precursor or hydrogen sulfide precursor. A variety of antioxidants can be used in the therapeutic composition. In some examples, the antioxidant can include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbic acid, ascorbyl palmitate, alpha tocopherol, potassium metabisulfite, sodium thiosulfate, propyl gallate, carotenoids, lipoic acid, ubiquinone, the like, or a combination thereof. In other examples, the antioxidant can include a plant-based powder blend rich in antioxidants such as polyphenols. In the case of cardiovascular disorders, oxidative stress and reactive oxygen species (ROS) can cause endothelial damage, progression of atherosclerosis, injury in sustained myocardial infarction and/or in ischemia reperfusion, the like, or a combination thereof. A deterioration in nitric oxide (NO) dependent vasorelaxation is a risk factor that can predispose individuals to cardiovascular disease. Plant-based antioxidants can also be used in the therapeutic composition. In some cases, the antioxidants can be derived from red grape skin extract, red grape seed extract, white grape skin extract, white grape seed extract, green tea extract, carrot juice or extract, tomato juice or extract, broccoli juice or extract, green cabbage juice or extract, onion juice or extract, garlic juice or extract, asparagus juice or extract, olive juice or extract, cucumber juice or extract, bilberry juice or extract, grapefruit juice or extract, papaya juice or extract, pineapple juice or extract, strawberry juice or extract, apple juice or extract, apricot juice or extract, cherry juice or extract, orange juice or extract, black currant juice or extract, beetroot, (tartar) cherry, kiwi fruit, watermelon, hawthorn berry, celery, cili fruit, jujube
fruit, broccoli, blue honeysuckle fruit, strawberry, yumberry, purple sweet potato, monk fruit, plum, and the like, or a combination thereof. The antioxidant can be present in the therapeutic composition in a variety of amounts. In some examples, the antioxidant can be present in the therapeutic composition in an amount sufficient to contribute to the antioxidant activity of the endothelial glycocalyx (EGX). In some examples, the antioxidant can be present in the therapeutic composition in a therapeutically effective amount. In some specific examples, the antioxidant can be present in the composition in an amount of from about 0.0001 wt% to about 90 wt%. In another example, the antioxidant can be present in the composition in an amount of from about 0.0001 wt% to about 30 wt%. In another example, the antioxidant can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%. In another example, the antioxidant can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%. In some cases, the composition can be free of antioxidant. In some further examples, the therapeutic composition can also include an endothelial glycocalyx regenerator. In one example, the glycocalyx regenerator can include a sulfated polysaccharide, a sulfated oligosaccharide, chito-oligosaccharides (COS), other glycans and their precursors such as glucosamine, hyaluronan and chondroitin sulfate, or combinations thereof. In another example, the glycocalyx regenerator can include rhamnan sulfate, fucoidan sulfate, carrageenan, or combinations thereof. In another example, the glycocalyx regenerator can be present in the composition in an amount of from about 0.0001 wt% to about 80 wt%. In another example, the glycocalyx regenerator can be present in the composition in an amount of from about 0.0001 wt% to about 30 wt%. In another example, the glycocalyx regenerator can be present in the composition in an amount of from about 0.0001 wt% to about 20 wt%. In another example, the glycocalyx regenerator can be present in the composition in an amount of from about 0.0001 wt% to about 10 wt%. In some cases, the composition can be free of glycocalyx regenerator. In some other examples, the therapeutic composition can also include a source of nitrate and/or nitrite. Dietary nitrate and nitrite are precursors of nitric oxide (NO) that plays important roles in reducing reactive oxygen species. In addition to the endothelial nitric oxide synthase, a significant portion of systemic nitric oxide may be generated by reduction of nitrate to nitrite to nitric oxide by other enzymatic systems including the one
that exists in the commensal gram-negative bacteria on the tongue. Nitric oxide is a vasodilator that increases blood flow. It also has anti-inflammatory, anticoagulant and antioxidant activities in relation to the development of atherosclerosis. It has been shown that dietary nitrate and nitrite lower blood pressure in humans. The therapeutic composition can include a variety of source of nitrate and nitrite. Non-limiting examples include thiamine mononitrate and nitrate and nitrite salts of sodium, potassium, calcium, magnesium, manganese, iron, copper, chromium and zinc. Also many fruits and vegetables are good sources of nitrate and nitrite. A non-exhausting list includes arugula, celery, cress, lettuce, chervil, beetroot, spinach, mustard greens, cabbage, fennel, leek, parsley, rocket, swiss chard, leafy chicory, Kohlrabi, radish, etc. Many herbs such as traditional Chinese medicinal herbs also contain an appreciable amount of nitrate and nitrite. They include, but are not limited to, danshen root (Radix salvia miltorrhizae), snakegourd fruit (Fructus trichosanthis), longstamen onion bulb (Bulbus allii macrostemi), sanchi (Radix notoginseng), ginseng (Radix ginseng), borneol (Borneolum syntheticum), and borneol (Cinnamomum). In some specific examples, the plant-based nitrate and nitrite can include a blend of powdered extracts. In still other examples, the plant-based nitrate and nitrite can include a blend of liquid extracts or juices. In some examples, the nitrate and nitrite can be present in the therapeutic composition in an amount from about 10 wt% to about 90 wt%. In other examples, the nitrate and nitrite can be present in an amount from about 20 wt% to about 80 wt%. As non-limiting examples, the therapeutic composition can include an NO precursor, an H2S precursor, and pharmaceutically acceptable carrier with one or more supplemental components such as an antioxidant, a glycocalyx regenerator, other cofactors supporting both endogenous and exogeneous NO pathways, and the like. When provided as a powdered supplement optional additives can be added such as, but not limited to, sweeteners, colorants, flavorants, preservatives, and the like. Furthermore, the therapeutic composition can also include one or more factors that optimize the eNOS function and activity. Non-limiting examples of suitable factors can include at least one of magnesium, zinc, pyridoxine (B6), folic acid (B9), vitamin B12, vitamin C, vitamin D, and tetrahydrobiopterin (BH4). The therapeutic composition can also include a pharmaceutically acceptable carrier. The nature of the pharmaceutically acceptable carrier can depend on the intended mode of administration. In some examples, the therapeutic composition can be formulated for
administration via injection. In other examples, the therapeutic composition can be formulated for oral administration. In yet another example, the therapeutic composition can be formulated for IV administration. Where the therapeutic composition is formulated for administration via injection, the pharmaceutically acceptable carrier can include one or more components suitable for such a composition. Non-limiting examples can include water, a solubilizing or dispersing agent, a tonicity agent, a pH adjuster or buffering agent, a preservative, a chelating agent, a bulking agent, the like, or a combination thereof. In some examples, an injectable therapeutic composition can include a solubilizing or dispersing agent. Non-limiting examples of solubilizing or dispersing agents can include polyoxyethylene sorbitan monooleates, lecithin, polyoxyethylene polyoxypropylene co- polymers, propylene glycol, glycerin, ethanol, polyethylene glycols, sorbitol, dimethylacetamide, polyethoxylated castor oils, n-lactamide, cyclodextrins, caboxymethyl cellulose, acacia, gelatin, methyl cellulose, polyvinyl pyrrolidone, the like, or combinations thereof. In some examples, an injectable therapeutic composition can include a tonicity agent. Non-limiting examples of tonicity agents can include sodium chloride, potassium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, dextrose, glycerin, propylene glycol, ethanol, trehalose, phosphate-buffered saline (PBS), Dulbecco’s PBS, Alsever’s solution, Tris-buffered saline (TBS), water, balanced salt solutions (BSS), such as Hank’s BSS, Earle’s BSS, Grey’s BSS, Puck’s BSS, Simm’s BSS, Tyrode’s BSS, and BSS Plus, the like, or combinations thereof. The tonicity agent can be used to provide an appropriate tonicity of the therapeutic composition. In one aspect, the tonicity of the therapeutic composition can be from about 250 to about 350 milliosmoles/liter (mOsm/L). In another aspect, the tonicity of the therapeutic composition can be from about 277 to about 310 mOsm/L. In some examples, an injectable therapeutic composition can include a pH adjuster or buffering agent. Non-limiting examples of pH adjusters or buffering agents can include a number of acids, bases, and combinations thereof, such as hydrochloric acid, phosphoric acid, citric acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, acetate buffers, citrate buffers, tartrate buffers, phosphate buffers, triethanolamine (TRIS) buffers, the like, or combinations thereof. Typically, the pH of the therapeutic composition can be from about 5 to about 9, or from about 6 to about 8.
In some examples, an injectable therapeutic composition can include a preservative. Non-limiting examples of preservatives can include ascorbic acid, acetylcysteine, bisulfite, metabisulfite, monothioglycerol, phenol, meta-cresol, benzyl alcohol, methyl paraben, propyl paraben, butyl paraben, benzalkonium chloride, benzethonium chloride, butylated hydroxyl toluene, myristyl gamma-picolimium chloride, 2-phenoxyethanol, phenyl mercuric nitrate, chlorobutanol, thimerosal, tocopherols, the like, or combinations thereof. In some examples, an injectable therapeutic composition can include a chelating agent. Non-limiting examples of chelating agents can include ethylenediaminetetra acetic acid, calcium, calcium disodium, versetamide, calteridol, diethylenetriaminepenta acetic acid, the like, or combinations thereof. In some examples, an injectable therapeutic composition can include a bulking agent. Non-limiting examples of bulking agents can include sucrose, lactose, trehalose, mannitol, sorbitol, glucose, rafinose, glycine, histidine, polyvinyl pyrrolidone, the like, or combinations thereof. Where the therapeutic composition is formulated for oral administration, the pharmaceutically acceptable carrier can include one or more components suitable for such a composition. In the case of solid oral compositions or dosage forms, the pharmaceutically acceptable carrier can include a variety of components suitable for forming a capsule, tablet, or the like. In the case of a liquid oral composition or dosage form, the pharmaceutically acceptable carrier can include a variety of components suitable for forming a dispersion, a suspension, a syrup, an elixir, or the like. In some specific examples, the therapeutic composition can be formulated as a tablet. In such examples, the therapeutic composition can typically include a binder. Non- limiting examples of binders can include lactose, calcium phosphate, sucrose, corn starch, microcrystalline cellulose, gelatin, polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP), hydroxypropyl cellulose, hydroxyethylcellulose, carboxymethyl cellulose (CMC), cellulose, other cellulose derivatives, the like, or combinations thereof. Where the therapeutic composition is formulated as a tablet, in some examples the therapeutic composition can also include a disintegrant. Non-limiting examples of disintegrants can include crosslinked PVP, crosslinked CMC, modified starch, sodium starch glycolate, the like, or combinations thereof. In some examples, the tablet can also include a filler. Non-limiting examples of fillers can include lactose, dicalcium phosphate, sucrose, microcrystalline cellulose, the like, or combinations thereof. In some further
examples, the tablet can include a coating. Such coatings can be formed with a variety of materials, such as hydroxypropyl methylcellulose (HPMC), shellac, zein, various polysaccharides, various enterics, the like, or combinations thereof. In some examples, the tablet can include a variety of other ingredients, such as anti- adherents (e.g. magnesium stearate, calcium stearate, for example), colorants (e.g. titanium dioxide, carmine, for example), glidants (e.g. fumed silica, talc, magnesium carbonate, for example), lubricants or anti-caking agents (e.g. talc, silicon dioxide, magnesium stearate, calcium stearate, stearic acid, for example) preservatives, desiccants, and/or other suitable tablet excipients, as desired. In some other examples, the therapeutic composition can be formulated as a capsule. In such examples, the capsule itself can typically include gelatin, hypromellose, HPMC, CMC, other plant-based capsule materials, the like, or combinations thereof. A variety of excipients can also be included within the capsule, such as binders, disintegrants, fillers, glidants, anti-caking agents, preservatives, coatings, the like, or combinations thereof, such as those listed above with respect to tablets, for example, or other suitable variations. In some examples, the therapeutic composition can be formulated as a liquid therapeutic composition or liquid oral dosage form. A liquid oral dosage form can include a variety of excipients, such as a liquid vehicle, a solubilizing agent, a thickener or dispersant, a preservative, a tonicity agent, a pH adjuster or buffering agent, a sweetener, a thickening agent, the like, or a combination thereof. Non-limiting examples of liquid vehicles can include water, ethanol, glycerol, propylene glycol, the like, or combinations thereof. Non-limiting examples of solubilizing agents can include banzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol-9, octoxynol, polyoxyethylene polyoxypropylene co-polymers, polyoxyl castor oils, polyoxyl hydrogenated castor oils, polyoxyl oleyl ethers, polyoxyl cetylstearyl ethers, polyoxyl stearates, polysorbates, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol, the like, or combinations thereof. Non-limiting examples of thickeners or dispersants can include sodium alginate, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, HPMC, CMC, microcrystalline cellulose, tragacanth, xanthan gum, bentonite, carrageenan, guar gum, colloidal silicon dioxide, the like, or combinations thereof. The preservative, tonicity agent, pH adjuster or buffering agent can typically be any of those described above with respect
to the injectable formulations or other suitable preservative, tonicity agent, pH adjuster or buffering agent. Sweeteners can include natural and/or artificial sweeteners, such as sucrose, glucose, fructose, stevia, erythritol, xylitol, aspartame, sucralose, neotame, acesulfame potassium, saccharin, advantame, sorbitol, the like, or combinations thereof, for example. In some examples, the therapeutic composition can be formulated as a functional food and/or medical food product such as a food bar, powder, or beverage. Food bars can be formulated to fit different dietary regiments for any specific purposes such as weight loss, energy, meal replacement, high protein, high fiber, low glycemic, etc. A food bar usually contains ingredients that supply energy-yielding nutrients such as carbohydrate, protein and lipid as well as other macro- and micronutrients including but not limited to vitamins and minerals. Other health promoting ingredients such fruit and vegetable powder may be included in the formulation in addition to filler, binder, emulsifier, water, humectant, flavor, color, sweetener, preservative, etc. The therapeutic composition can be formulated into a food bar with other ingredients to achieve desirable health benefits, taste, texture, flavor and stability. Similarly, the therapeutic composition may be formulated into a powder such as a protein powder, meal replacement powder, or functional beverage dry mix. It can also be formulated into a functional drink. A ready to drink beverage may contain other ingredients including various nutrients, health promoting agents, pH adjustor (acidity regulator), electrolyte, flavor, sweetener, stabilizing agent, color, preservative, etc. The present disclosure also describes oral dosage forms. The oral dosage forms can include a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to treat endothelial dysfunction. The oral dosage form can also include a pharmaceutically acceptable carrier. The types of NO precursors or hydrogen sulfide precursors that can be included in the oral dosage forms are generally described above with respect to the therapeutic compositions. In some examples, the oral dosage form can include NO precursors or hydrogen sulfide precursors in an amount from about 0.5 mg to about 5,000 mg of NO precursors, hydrogen sulfide precursors, or both. In some other examples, the oral dosage form can include from about 5 mg to about 1500 mg of NO precursors, or hydrogen sulfide precursors, or both per dose. In some additional examples, the oral dosage form can include from about 10 mg to about 800 mg of NO precursors, or hydrogen sulfide precursors, or
both per dose. In still other examples, the oral dosage form can include from about 50 mg to about 300 mg of NO precursors, or hydrogen sulfide precursors, or both per dose. In some additional examples, the oral dosage forms can include an antioxidant, either antioxidant enzymes and/or nonenzymatic antioxidants, as described above with respect to the therapeutic compositions. In some examples, the oral dosage form can include the plant antioxidant in an amount from about 20 mg to about 20,000 mg per dose. In other examples, the antioxidant can be present in the oral dosage form in an amount from about 100 mg to about 600 mg per dose. In still other examples, the antioxidant can be present in the oral dosage form in an amount from about 125 mg to about 350 mg per dose. In some specific examples, the antioxidant can be included in the oral dosage form in the form of a powdered blend of edible plant materials with antioxidant activity, such as those described above. In other examples, the antioxidant can be included in the oral dosage form in the form of a liquid blend of edible plant materials with antioxidant activity, such as those described above. In some additional examples, the oral dosage forms can include a source of nitrate and nitrite, as described above with respect to the therapeutic compositions. In some examples, the oral dosage form can include nitrate and nitrite in an amount from about 20 mg to about 2,000 mg per dose. In other examples, nitrate and nitrite can be present in the oral dosage form in an amount from about 50 mg to about 1,000 mg per dose. In still other examples, nitrate and nitrite can be present in the oral dosage form in an amount from about 200 mg to about 600 mg per dose. In some specific examples, nitrate and nitrite can be included in the oral dosage form in the form of a powdered blend of edible plant materials with nitrate and nitrite, such as those described above. In other examples, nitrate and nitrite can be included in the oral dosage form in the form of a liquid blend of edible plant materials with nitrate and nitrite, such as those described above. In some specific examples, the oral dosage forms can be solid oral dosage forms. Where this is the case, the solid oral dosage forms can include any pharmaceutically acceptable carrier components suitable for a solid oral dosage form. In some specific examples, the solid oral dosage form can include one or more of a binder, a disintegrant, a filler, an anti-adherent, a colorant, a glidant, a lubricant or anti-caking agent, a preservative, a desiccant, the like, or a combination thereof, such as those described above with respect to the therapeutic compositions. In some examples, the solid oral dosage form can be
formulated as a tablet. In other examples, the solid oral dosage form can be formulated as a two-piece hard capsule or a hermetically sealed soft-gel capsule. In some additional specific examples, the oral dosage forms can be liquid oral dosage forms. Where this is the case, the liquid oral dosage forms can include any pharmaceutically acceptable carrier components suitable for a liquid oral dosage form. In some specific examples, the liquid oral dosage form can include a liquid vehicle, a solubilizing agent, a thickener or dispersant, a preservative, a tonicity agent, a pH adjuster or buffering agent, a sweetener, the like, or a combination thereof, such as those described above. In some examples, the dosage forms or therapeutic compositions described herein can be disposed in a suitable container. Such containers can include multiple-use containers or single use containers. Non-limiting examples can include bottles, vials, blister packs, bags, or the like. In some examples, the container can be an amber colored container or other suitable container configured to protect the dosage form or therapeutic composition from light. In yet other examples, the container can include instructions and dosing information for the dosage form or therapeutic composition. The container can include a variety of materials, such as polyethylene, polypropylene, polycarbonate, polyvinyl chloride, glass, the like, or a combination thereof. In yet additional alternatives, the therapeutic compositions described herein can be used as a food additive to fortify a food supply for general population. For example, the therapeutic composition can be safely introduced into a systemic food supply such as, but not limited to, milled grain flours, pastas, breakfast cereals, bread, soup or soup mixes, food bars, spices, condiments, dairy products, beverages, drink mixes, frozen food items, pastries, cookies and crackers, snacks, or the like. As an example formulation, a therapeutic composition can include two NO precursors, an H2S precursor, an endothelial glycocalyx regenerating compound, a nonenzymatic antioxidant, a plant-based antioxidant, and one or more eNOS cofactors. In a further example, the two NO precursors can include potassium nitrate (100-500 mg/serving) and beetroot extract (50-2000 mg/serving), the H2S precursor can include SAC (100-1000 mg/serving) and thiamine mononitrate (1-100 mg/serving), the eGRC includes MNE (25-500 mg/serving), the nonenzymatic antioxidant includes Vitamin C (100-300 mg/serving), the plant-based antioxidant includes bilberry extract (50-500 mg/serving), and
the eNOS cofactors include magnesium (20-200 mg/serving), zinc (2-30 mg/serving), methyl cobalamin (10-200 mcg/serving), and cholecalciferol (10-200 mcg/serving). The present disclosure also describes a method of treating endothelial dysfunction. The method can include identifying endothelial glycocalyx (EGX) and/or endothelial dysfunction of the subject and administering to the subject a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount and at a frequency sufficient to stabilize and restore the EGX and endothelial function. In one aspect, damage in the EGX and endothelium can be detected using various blood markers, imaging technologies, and functional tests. For example, biomarkers, Alpha Elution Technology, dark field microscopy, coronary epicardial vasoactivity, flow-mediated dilation, plethysmography, and EndoPat may be used to assess EGX or endothelial dysfunction. Administration of the combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor to a subject can be performed in a number of ways. In some examples, the combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor can be administered orally. Oral administration can include administration as a solid oral dosage form (e.g. a tablet, a capsule, etc.) or a liquid oral dosage form (e.g. a solution, a suspension, a syrup, an elixir, a gel, etc.). In some other examples, administration can be performed via injection (e.g. intravenous, intra-arterial, intramuscular, sub-cutaneous, etc.). Further, where the composition is administered via injection, it can be injected via a bolus injection or via metered infusion. Other forms of administration can also include topical administration, transdermal administration, inhalation, ophthalmic administration, nasal administration, otic administration, administration as a suppository, or the like. The particular therapeutic composition administered can be any of those described herein, or the like. Further, in some examples, the combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor can be administered as a composition or dosage form, such as those described herein. In some examples, the combination of the NO precursor and the H2S precursor can be administered in an amount from about 1 mg to about 15,000 mg per dose. In some other examples, the oral dosage form can be administered in an amount from about 10 mg to about 1500 mg of the combination of the NO precursor and the H2S precursor per dose. In some additional examples, the oral dosage form can be administered in an amount from about 30 mg to about 300 mg of the combination of the NO precursor and the H2S precursor per dose. In
still other examples, the oral dosage form can be administered in an amount from about 50 mg to about 200 mg of the combination of the NO precursor and the H2S precursor per dose. It is also noted that where the combination of the NO precursor and the H2S precursor is administered as part of a solid oral dosage form, a dose can include one, two, three, four, or more capsules, tablets, etc. The combination of the NO precursor and the H2S precursor can be administered at a variety of frequencies. In some examples, a dose of the combination of the NO precursor and the H2S precursor can be administered at a frequency of from once daily to four times daily. In some examples, a dose of the combination of the NO precursor and the H2S precursor can be administered once per day, twice per day, three times per day, four times per day, or more. In other examples, the combination of the NO precursor and the H2S precursor can be administered at a frequency of from about once every two days, three days, five days, or seven days, for example. Thus, a variety of suitable administration frequencies can be employed with the present methods. Further, administration can continue for a variety of durations, depending on the desired treatment outcome. In some examples, administration can continue while symptoms of ED persist. In other examples, administration can be ongoing as either a prophylactic or intervention treatment. In still other examples, administration can continue until the ED has resolved or a threshold level of NO has been reached. Other suitable durations of administration can also be employed, as desired. As a general guideline, administration duration can be from about 2 weeks to about 24 months, and often from 2 months to 12 months. In some examples, the combination of the NO precursor and the H2S precursor can be administered in connection (e.g. co-administered) with another active agent. In some examples, the second active agent can include an antioxidant, nitrate, nitrite, or a combination thereof, as described elsewhere herein. The present method takes advantage of synergistic mechanisms to generate and store NO which sustains a therapeutic level of NO in the vascular system beyond what can achieved by the existing approaches. Thus, the amount and frequency of therapeutic composition can be adjusted to achieve an increase of bioavailable NO for treatment of ED. In some cases, such an increase can be sustained for a period of at least 12 hours, 24 hours, or 48 hours. In many examples, the increase can be sustained for at least 24 hours such that daily administration can be effective for longer term treatment and recovery.
It is also noted that the present methods can be used to treat a number of adverse health conditions related to endothelial dysfunction. Non-limiting examples of adverse health conditions can include coronary heart disease, myocardial infarction, carotid artery disease, stroke, peripheral artery disease, aneurysms, chronic kidney disease, erectile dysfunction, hypertension, Alzheimer’s disease, vascular dementia, diabetes, Raynaud’s disease, sleep apnea, the like, or a combination thereof. EXAMPLES The following examples are provided to promote a clearer understanding of certain embodiments of the present invention and are in no way meant as a limitation thereon. Example 1 – A Basic NO Precursor Composition (Formula 1) A basic NO Precursor containing composition was prepared by using the components set forth in Table I. The composition was prepared by weighing all of the components into a clean stainless-steel container and combining in a substantially inert environment to form a solution. A predetermined quantity of the fill material was disposed into a hard capsule to get the target NO precursor dose per dosage unit. The capsules were allowed to cool at room temperature, banded (if required) and packaged in a HDPE bottle and tightly closed with an appropriate lid. TABLE I (Formula 1)
The composition was evaluated for its ability to increase NO production and availability. A healthy young male ingested a single dose of the composition in the morning only and his saliva nitrite (NO2) was determined with Berkeley Test® Nitric Oxide Test Strip over 12 hours (Formula 1 in Table II). Saliva nitrite is a surrogate marker of NO bioavailability as saliva conversion of nitrate to nitrite (NO3) is a step to produce NO via exogenous pathway inside the body. TABLE II (Saliva Nitrite)
Saliva nitrite at the baseline was very low and relatively flat over 12 hours. After ingesting the composition (Formula 1), saliva nitrite started to increase at 4 hour and reached the peak at 6 hours. After 12 hours, saliva nitrite dropped back to the initial level. It is clear that intake of formula 1 (dashed line) led to a marked increase of NO bioavailability over baseline (solid line) for at least 12 hours (Figure 1). Example 2 – A Basic NO and H2S Precursor Composition (Formula 2) An H2S precursor containing composition was prepared by adding N-acetyl cysteine to the composition in Example 1 (Formula 2 in Table III). The composition was prepared by weighing all of the components into a clean stainless-steel container and combining in a substantially inert environment to form a solution. A predetermined quantity of the fill material was disposed into a capsule to get the target H2S precursor dose per dosage unit. The capsules were allowed to cool at room temperature, banded (if required) and packaged in a HDPE bottle and tightly closed with an appropriate lid. TABLE III (Formula 2)
The composition was evaluated for its ability to increase NO production and availability. A healthy young male ingested a single dose of the composition in the morning only and his salivary nitrite (NO2) was determined with Berkeley Test® Nitric Oxide Test Strip over 12 hours (Formula 2 in Table II). Compared to baseline, saliva nitrite after ingesting Formula 2 (dotted line) was higher than the baseline (solid line) at every time point (Figure 2). In addition, saliva nitrite after ingesting Formula 2 was higher than that after ingesting Formula 1 (dashed Line) for 4 of the 7 time points (from 2 hours to 8 hours). It is worth noting the starting saliva nitrite was higher at 7.5 mg/L for Composition 1 than 5 mg/L for Formula 2. At 12 hours, saliva nitrite dropped back to the initial value for Formula 1. In contrast, saliva nitrite is still higher than the initial value for Formula 2 at the 12-hour mark. Therefore, it is concluded that Formula 2 is superior to Formula 1. It sustains a higher bioavailable NO for more than 12 hours. Example 3 – A NO Precursor with a eGRC (Formula 3) The NO precursor composition in Example 1 was enhanced by adding an endothelial glycocalyx regenerating compound (eGRC), a green seaweed Monostroma nitidum extract (MNE) as Formula 3 in Table IV and a method similar to that described in Examples 1 and 2. TABLE IV (Formula 3)
The composition was evaluated for its ability to increase NO production and availability. A healthy young male ingested a single dose of the composition in the morning only and his salivary nitrite (NO2) was determined with Berkeley Test® Nitric Oxide Test Strip over 12 hours (Formula 3 in Table II). As shown in FIG.3, all data points of saliva nitrite for Formula 3 (dotted line) were higher than those of baseline (solid line). Also 3 of 7 data points (2, 4 and 8 hour) of Formula 3 are higher than those of Formula 1 (dashed line). It is worth noting the starting saliva nitrite was higher at 7.5 mg/L for Formula 1 than 5 mg/L for Formula 3. At 12 hours, saliva nitrite dropped back to the initial value for Formula 1. In contrast, saliva nitrite was still higher than the initial value for Formula 3 at the 12hour mark. Therefore, it is concluded that Formula 3 is superior to Formula 1. It sustains a higher bioavailable NO for more than 12 hours. Example 4 – An Advanced NO Precursor with H2S Precursor Composition (Formula 4) An advanced composition was prepared by including plant based NO precursor with H2S precursor (Formula 4 in Table V). This is a plant-based formula with NO and H2S precursors derived from plant materials. The plant-based precursors have the advantage of containing other benefiting phytochemicals such as antioxidant polyphenols. They may also have better absorption and release profile to increase NO bioavailability. Formula 4
also includes additional plant polyphenols and vitamin D3, both increase eNOS activity and NO bioavailability. This formula actually contains less NO precursor and less H2S precursor than Formula 3. However, it was expected to work better due to the synergistic effect of its components. The composition was prepared by weighing all of the components into a clean stainless-steel container and combining in a substantially inert environment to form a solution. The composition was packaged and stored in a container. TABLE V (Formula 4)
The composition was evaluated for its ability to increase NO bioavailability. A healthy young male ingested a single dose of the composition in the morning only. His saliva nitrite
was determined with Berkeley Test® Nitric Oxide Test Strip and his saliva S-nitrosothiols (SNOS) determined with MyFitStrip® Saliva SNOS Test Strip over 12 hours (Table VI and VII). TABLE VI (Saliva Nitrite)
Saliva nitrite at the baseline was very low and almost flat (solid line, Figure 4). With Formula 4 (dashed line), saliva nitrite increased throughout the 12 hours. Saliva nitrite increased by 700% at the peak of 2 hours. At the 12-hour mark, saliva nitrite was still much higher than the initial timepoint and also the baseline. In summary, this advance formula boosted saliva nitrite to a much higher level and sustained the increase NO bioavailability longer. Table VII below presents the data on saliva SNOS. There was essentially no detectable SNOS before ingesting Formula 4. After Formula 4, saliva SNOS jumped to 80 mg/L in 2 hours and stayed higher for 12 hours. At the 12 hours, saliva SNOS was still much higher than the baseline. These data support the conclusion that H2S precursor stimulates H2S production inside the body. It also leads to a dramatic increase of NO storage inside the body which helps sustain an increased NO bioavailability for more than 12 hours. TABLE VII (Saliva S-nitrosothiols)
In addition, the composition was evaluated for its ability to increase saliva nitrite, to improve endothelial function, and to reduce blood pressure in a milder hypertensive male over 24 hours (Table VIII, IX, and XI). At time zero, saliva nitrite levels as measure with Berkeley Test® Nitric Oxide Test Strip are the same for the baseline and Formula 4 (Table VIII). However, saliva nitrite for Formula 4 stayed much higher than the baseline over 24 hours. The increase was 8-fold at 4 and 6 hours. These data demonstrate Formula 4 sustained saliva nitrite and, therefore, a marked increase of NO bioavailability for 24 hours. TABLE VIII (Saliva Nitrite)
The subject had a milder systolic hypertension (Table IX) and was under no medication. After ingesting Formula 4 in the morning, his systolic blood pressure dropped consistently from 2 hours to 20 hours. In essence, the hypotensive effect of Formula 4 lasted for 24 hours. The formula is indicated for CVD. TABLE IX (Blood Pressure)
As discussed earlier, endothelial dysfunction leads to CVD including hypertension. Endothelial function of the subject was evaluated by pulse wave analysis (PVA) with SA- 3000P from Medicore. The medical device generates an accelerated plethysmogram (APG) waveform. The waveform pattern can be used to assess the endothelial function and CVD risk. Table X lists the waveform types and corresponding vascular health conditions. Table X (Waveform Pattern)
PWA shows the subject had suboptimal circulation and vessel condition with waveform type 4 (Table XI). After ingesting a single serving of Formula 4, the waveform improved in 2 hours. The beneficial effect lasted for 24 hours. This is not surprising and confirmed that Formula 4 sustained an increased NO bioavailability for 24 hours. TABLE XI (APG Waveform)
Furthermore, a small human study was completed with 5 uncontrolled hypertensive patients at a research medical clinic. Each subject took a single serving of Formula 4 once in the morning every day for 2 weeks. Saliva nitrite was measured with Berkeley Test® Nitric Oxide Test Strip and saliva S-nitrosothiols were measured with MyFitStrip® SNOS Test Strip before and after taking the composition (Formula 4). Blood pressures were also determined. Data of the 5 subjects are analyzed and presented in the Table XII, XII and XIV.
During visit 1, saliva nitrite of subjects was measured with Berkeley Test® Nitric Oxide Test Strip. The average saliva nitrite was 45 mg/L before ingesting Formula 4. The number significantly increased to 370 mg/L 2 hours after ingesting Formula 4 (p=0.014). After 2 weeks, the average saliva nitrite before ingesting Formula 4 was 280 mg/L during visit 2. This number is marked higher than 45 mg/L 2 weeks ago. The increase almost reaches a statistical significance at a p-value of 0.069. The elevated saliva nitrite before ingesting Formula 4 after 2 weeks indicates the daily dose of Formula 4 has a lasting effect on increasing NO bioavailability for more than 24 hours. Two hours after ingesting Formula 4 during visit 2, average saliva nitrite further climbed to 450 mg/L, a significant 10-fold increase compared to the original level at 45 mg/L. Research data indicate saliva nitrite at above 200 mg/L is generally associated with a hypotensive benefit. This is normally achieved with a higher level of NO precursor than is present in Formula 4. However, such a saliva nitrite level usually lasts anywhere from less than an hour to a few hours with current products on the market. On the other hand, Formula 4 surpasses 200 mg/L within 2 hours and sustains the level for at least 24 hours after repeated single daily dosing of 2 weeks or less. Again, these data clearly demonstrate the effective results to increase bioavailable NO. TABLE XII (Saliva NO2)
Average saliva SNOS at the baseline was 10 mg/L (Table XIII). Two hours after dosing with Formula 4, saliva SNOS increased to 64 mg/L and reached a statistical significance at a p-Value of 0.005. Such a 6-fold increase parallels the increase of saliva NO2. After 2 weeks, average saliva SNOS further increased to 80 mg/L after dosing. Again this number mimics the pattern of saliva NO2. Formula 4 undoubtedly increased H2S production and NO storage inside the body. It also likely increased and sustained NO bioavailability via some other mechanisms. To our knowledge, this is the first time such data are collected to corroborate and support a long-lasting NO bioavailability by a single daily dosing of a synergistic therapeutic composition.
TABLE XIII (Saliva SNOS)
Patients were under medical care and their hypertension being treated. However, their systolic blood pressure was not under control at an average of 138.9 mmHg before a single daily dosing with formula 4. After 2 weeks, the average systolic blood pressure dropped more than 10 points to 128.7 mmHg. Basically, treatment of Formula 4 for 2 weeks brought their systolic blood pressure under control and into a normal range. The reduction has a p-value of 0.081 and would be expected to reach a statistical significance with a larger sample size. At the same time, the average diastolic pressure dropped by more than 5 points from 78.9 to 73.7 mmHg. A 5-point reduction of diastolic pressure in 2 weeks is impressive by any standard given the fact the patients only suffered high systolic blood pressure. These hypertension data clearly demonstrate Formula 4 affected a long-lasting effect on NO bioavailability which led to a hypotensive benefit. TABLE XIV (Blood Pressure)
Example 5 – An Advanced NO Precursor with H2S Precursor Composition with an eGRC (Formula 5) The composition was prepared using the components set forth in Table XV (Formula 5), by adding the eGRC MNE in the composition of Example 4. MNE repairs, regenerates and restores the endothelial glycocalyx (EGX). A healthy and optimal EGX enables eNOS to synthesize NO. It also houses extracellular superoxide dismutase (exSOD). exSOD that controls oxidative stress by ROS at the endothelium and makes more NO available for its biological function. Formula 5 has the advantage of additional synergistic effects to boost NO production and availability.
TABLE XV (Formula 5)
The composition was evaluated for its ability to increase NO production and availability. A healthy young male ingested a single serving of Formula 5 in the morning only and his saliva nitrite (NO2) was determined with MyFitStrip® Saliva SNOS Test Strip for 12 hours. As seen in Table VI, saliva nitrite with Formula 5 was significantly higher than the baseline throughout the period. In fact, 4 of the 7 data points during the 12 hours are also higher than those with Formula 4 at 4, 6, 8 and 12 hours. Figure 4 clearly shows an overall higher NO bioavailability sustained by Formula 5 (dotted line) compared that with Formula 4 (dashed line). It is also observed that such an effect goes far beyond 12 hours. Based on the 24-hour effect of formula 4 demonstrated by other data, Formula 5 will
sustain a higher NO bioavailability for at least 24 hours especially with repeated single daily dosing for 2 weeks. The data indicate Formula 5 is even better than Formula 4 as an innovative therapeutic composition to increase vascular NO for the treatment of ED and related condition such as hypertension. It is understood that the above-described various types of compositions, dosage forms and/or modes of applications are only illustrative of preferred embodiments of the present invention. Numerous modifications and alternative arrangements may be devised by those skilled in the art without departing from the spirit and scope of the present invention and the appended claims are intended to cover such modifications and arrangements. Thus, while the present invention has been described above with particularity and detail in connection with what is presently deemed to be the most practical and preferred embodiments of the invention, it will be apparent to those of ordinary skill in the art that variations including, but not limited to, variations in size, quantities, materials, shape, form, function and manner of operation, assembly and use may be made without departing from the principles and concepts set forth herein.
Claims
CLAIMS What is claimed is: 1. A therapeutic composition for treating endothelial dysfunction, comprising: a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to sustain an increase of bioavailable NO for treatment of endothelial dysfunction; and a pharmaceutically acceptable carrier.
2. The therapeutic composition of claim 1, wherein the NO precursor comprises L- arginine, L-arginine alpha-ketoglutarate, L-citrulline, or combinations thereof.
3. The therapeutic composition of claim 1, wherein the NO precursor comprises inorganic nitrite, inorganic nitrate, organic nitrate, or combinations thereof.
4. The therapeutic composition of claim 1, wherein the NO precursor comprises nitrite or nitrate salts of sodium, potassium calcium, magnesium, manganese, iron, copper, chromium, zinc, or combinations thereof.
5. The therapeutic composition of claim 1, wherein the NO precursor is derived from arugula, celery, cress, lettuce, chervil, beetroot, spinach, mustard greens, cabbage, fennel, leek, parsley, rocket, swiss chard, leafy chicory, Kohlrabi, radish, or combinations thereof.
6. The therapeutic composition of claim 1, wherein the NO precursor is derived from danshen root (Radix salvia miltorrhizae), snakegourd fruit (Fructus trichosanthis), longstamen onion bulb (Bulbus allii macrostemi), sanchi (Radix notoginseng), ginseng (Radix ginseng), borneol (Borneolum syntheticum), and borneol (Cinnamomum), or combinations thereof.
7. The therapeutic composition of claim 1, wherein the NO precursor is a blend of powdered extracts.
8. The therapeutic composition of claim 1, wherein the NO precursor is a blend of liquid extracts.
9. The therapeutic composition of claim 1, wherein the NO precursor is present in the composition in an amount of from about 10 wt% to about 90 wt%.
10. The therapeutic composition of claim 1, wherein the hydrogen sulfide precursor comprises sodium hydrosulfide (NaHS), sodium sulfide, N-acetyl cysteine (NAC), S-allyl cysteine, glutathione (GSH), a garlic-derived organic polysulfide, a sulfated oligosaccharide, a sulfated polysaccharide, a natural isothiocyanate, other organosulfur compounds (OSCs), synthetic H2S donors such as phosphorodithioate derivatives, NOSH compounds which act as both NO and H2S precursors, or combinations thereof.
11. The therapeutic composition of claim 1, wherein the hydrogen sulfide precursor is present in the composition in an amount of from about 10 wt% to about 90 wt%.
12. The therapeutic composition of claim 1, further comprising an antioxidant.
13. The therapeutic composition of claim 12, wherein the antioxidant comprises antioxidant enzymes of superoxide dismutase (SOD), catalase, glutathione peroxidase, or combinations thereof, or non-enzymatic antioxidants of NAC, glutathione, vitamin C, lipoic acid, polyphenols, carotenoids, vitamin E, or combinations thereof.
14. The therapeutic composition of claim 12, wherein the antioxidant is present in the composition in an amount of from about 1 wt% to about 80 wt%.
15. The therapeutic composition of claim 1, further comprising an endothelial glycocalyx regenerator.
16. The therapeutic composition of claim 15, wherein the glycocalyx regenerator comprises a sulfated polysaccharide, a sulfated oligosaccharide, chito- oligosaccharides (COS), or combinations thereof.
17. The therapeutic composition of claim 15, wherein the glycocalyx regenerator comprises rhamnan sulfate, fucoidan sulfate, carrageenan, or combinations thereof.
18. The therapeutic composition of claim 15, wherein the glycocalyx regenerator is present in the composition in an amount of from about 10 wt% to about 80 wt%.
19. The therapeutic composition of claim 1, wherein the pharmaceutically acceptable carrier comprises water, a solubilizing agent, a dispersing agent, a tonicity agent, a pH adjuster, a buffering agent, a preservative, a chelating agent, a bulking agent, a binder, a disintegrant, a filler, a glidant, a lubricant, a sweetener, a thickening agent, eNOS cofactors, or a combination thereof, wherein cofactors are at least one of magnesium, zinc, pyridoxine (B6), folic acid (B9), vitamin B12, vitamin C, vitamin D, and tetrahydrobiopterin (BH4).
20. The therapeutic composition of claim 1, wherein the NO precursor includes two NO precursors as potassium nitrate (at 100-500 mg/serving) and beetroot extract (at 50- 2000 mg/serving), the H2S precursor is fermented black garlic extract (at 100-1000 mg/serving) and vitamin B1 (at 1-100 mg/serving), and the composition further comprises an endothelial glycocalyx regenerating compound which is Monostroma nitidum extract (at 25-500 mg/serving), a nonenzymatic antioxidant which is Vitamin C (at 100-300 mg/serving), a plant-based antioxidant which is bilberry extract (at 50-500 mg/serving), and multiple eNOS cofactors which include magnesium (at 20-200 mg/serving), zinc (at 2-30 mg/serving), methyl cobalamin (at 10-200 mcg/serving), and cholecalciferol (at 10-200 mcg/serving).
21. A method of treating endothelial dysfunction in a subject, comprising: administering to the subject a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount and at a frequency sufficient to stabilize and reverse damage in the endothelial glycocalyx (EGX).
22. The method of claim 21, wherein administering is performed orally or via injection.
23. The method of claim 21, wherein the NO precursor comprises L-arginine, L- arginine alpha-ketoglutarate, L-citrulline, or combinations thereof.
24. The method of claim 21, wherein the NO precursor comprises inorganic nitrite, inorganic nitrate, organic nitrate, or combinations thereof.
25. The method of claim 21, wherein the NO precursor comprises nitrite or nitrate salts of sodium, potassium calcium, magnesium, manganese, iron, copper, chromium, zinc, or combinations thereof.
26. The method of claim 21, wherein the NO precursor is derived from arugula, celery, cress, lettuce, chervil, beetroot, spinach, mustard greens, cabbage, fennel, leek, parsley, rocket, swiss chard, leafy chicory, Kohlrabi, radish, or combinations thereof.
27. The method of claim 21, wherein the NO precursor is derived from danshen root (Radix salvia miltorrhizae), snakegourd fruit (Fructus trichosanthis), longstamen onion bulb (Bulbus allii macrostemi), sanchi (Radix notoginseng), ginseng (Radix ginseng), borneol (Borneolum syntheticum), and borneol (Cinnamomum), or combinations thereof.
28. The method of claim 21, wherein the NO precursor is a blend of powdered extracts.
29. The method of claim 21, wherein the NO precursor is a blend of liquid extracts.
30. The method of claim 21, wherein the NO precursor is administered in an amount from about 50 mg to about 1000 mg per dose.
31. The method of claim 21, wherein administering is performed at a frequency of once or twice daily.
32. The method of claim 21, wherein the hydrogen sulfide precursor comprises sodium hydrosulfide (NaHS), sodium sulfide, N-acetyl cysteine (NAC), S-allyl cysteine, glutathione (GSH), a garlic-derived organic polysulfide, a sulfated oligosaccharide, a sulfated polysaccharide, a natural isothiocyanate, other organosulfur compounds (OSCs), synthetic H2S donors such as phosphorodithioate derivatives, NOSH compounds, or combinations thereof.
33. The method of claim 21, wherein the hydrogen sulfide precursor is administered in an amount from about 10 mg to about 2000 mg per dose.
34. The method of claim 21, further comprising identifying EGX or endothelial dysfunction of the subject.
35. The method of claim 34, wherein identifying comprises at least one of biomarkers, Alpha Elution Technology, dark field microscopy, coronary epicardial vasoactivity, flow-mediated dilation, plethysmography, and EndoPat.
36. The method of claim 21, further comprising administering an antioxidant.
37. The method of claim 21, further comprising administering a glycocalyx regenerator.
38. An oral dosage form, comprising: a combination of a nitric oxide (NO) precursor and a hydrogen sulfide (H2S) precursor in an amount sufficient to treat endothelial dysfunction; and a pharmaceutically acceptable carrier.
39. The oral dosage form of claim 38, wherein the NO precursor comprises L-arginine, L-arginine alpha-ketoglutarate, L-citrulline, or combinations thereof.
40. The oral dosage form of claim 38, wherein the NO precursor comprises inorganic nitrite, inorganic nitrate, organic nitrate, or combinations thereof.
41. The oral dosage form of claim 38, wherein the NO precursor comprises nitrite or nitrate salts of sodium, potassium calcium, magnesium, manganese, iron, copper, chromium, zinc, or combinations thereof.
42. The oral dosage form of claim 38, wherein the NO precursor is derived from arugula, celery, cress, lettuce, chervil, beetroot, spinach, mustard greens, cabbage, fennel, leek, parsley, rocket, swiss chard, leafy chicory, Kohlrabi, radish, or combinations thereof.
43. The oral dosage form of claim 38, wherein the NO precursor is derived from danshen root (Radix salvia miltorrhizae), snakegourd fruit (Fructus trichosanthis), longstamen onion bulb (Bulbus allii macrostemi), sanchi (Radix notoginseng), ginseng (Radix ginseng), borneol (Borneolum syntheticum), and borneol (Cinnamomum), or combinations thereof.
44. The oral dosage form of claim 38, wherein the NO precursor is administered in an amount from about 50 mg to about 1000 mg per dose.
45. The oral dosage form of claim 38, wherein the hydrogen sulfide precursor comprises sodium hydrosulfide (NaHS), sodium sulfide, N-acetyl cysteine (NAC), S-allyl cystine (SAC), glutathione (GSH), a garlic-derived organic polysulfide, a sulfated oligosaccharide, a sulfated polysaccharide, a natural isothiocyanate, other organosulfur compounds (OSCs), synthetic H2S donors such as phosphorodithioate derivatives, NOSH compounds, or combinations thereof.
46. The oral dosage form of claim 38, wherein the oral dosage form is formulated as a solid oral dosage form.
47. The oral dosage form of claim 46, wherein the pharmaceutically acceptable carrier of the solid oral dosage form comprises a filler, a binder, a glidant, a disintegrating agent, a lubricant, or a combination thereof.
48. The oral dosage form of claim 46, further comprising an exterior coating.
49. The oral dosage form of claim 38, wherein the oral dosage form is formulated as a liquid oral dosage form.
50. The oral dosage form of claim 49, wherein the pharmaceutically acceptable carrier of the liquid oral dosage form comprises a solubilizing agent, a dispersing agent, a thickener, a sweetener, a pH adjuster, a buffering agent, a tonicity agent, a preservative, or a combination thereof.
51. The oral dosage form of claim 38, further comprising an antioxidant.
52. The oral dosage form of claim 38, further comprising a glycocalyx regenerator.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163153867P | 2021-02-25 | 2021-02-25 | |
US63/153,867 | 2021-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022182968A1 true WO2022182968A1 (en) | 2022-09-01 |
Family
ID=83049530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/017869 WO2022182968A1 (en) | 2021-02-25 | 2022-02-25 | Synergistic compositions and methods to increase vascular nitric oxide to treat endothelial dysfunction and related conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022182968A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050085548A1 (en) * | 1997-04-10 | 2005-04-21 | Kaesemeyer Wayne H. | Method and formulation for treating vascular disease |
US20100143503A1 (en) * | 2006-12-22 | 2010-06-10 | Ikaria, Inc. | Combinations of nitric oxide and sulfide and methods of use and manufacture thereof |
US20130071494A1 (en) * | 2008-06-13 | 2013-03-21 | Nathan S. Bryan | Nitrite formulations and their use as nitric oxide prodrugs |
US20160296603A1 (en) * | 2015-04-08 | 2016-10-13 | Microvascular Health Solutions, LLC | Synergistic glycocalyx treatment compositions and methods |
-
2022
- 2022-02-25 WO PCT/US2022/017869 patent/WO2022182968A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050085548A1 (en) * | 1997-04-10 | 2005-04-21 | Kaesemeyer Wayne H. | Method and formulation for treating vascular disease |
US20100143503A1 (en) * | 2006-12-22 | 2010-06-10 | Ikaria, Inc. | Combinations of nitric oxide and sulfide and methods of use and manufacture thereof |
US20130071494A1 (en) * | 2008-06-13 | 2013-03-21 | Nathan S. Bryan | Nitrite formulations and their use as nitric oxide prodrugs |
US20160296603A1 (en) * | 2015-04-08 | 2016-10-13 | Microvascular Health Solutions, LLC | Synergistic glycocalyx treatment compositions and methods |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vitamin | Fact sheet for health professionals | |
ES2361740T3 (en) | COMPOSITIONS THAT INCLUDE VITAMIN K TO PREVENT HYPERTENSION, LEFT VENTRICULAR HYPERTROPHY, CONGESTIVE HEART FAILURE, MYOCARDIAL INFARCTION, APOPLEJIA AND CORONARY HEART DISEASE THROUGH PREVENTION RELEASE. | |
US6299896B1 (en) | Multi-vitamin and mineral supplement | |
US8703725B2 (en) | Nutritional compositions | |
US6361800B1 (en) | Multi-vitamin and mineral supplement | |
US6620440B1 (en) | Nutritive composition for cardiovascular health | |
US11478506B2 (en) | Dietary supplements | |
US11285124B2 (en) | Compositions and methods for increasing muscle mass and strength, treating skin, reducing wear and degradation from aging and exposure and improving recovery from stress such as exercise and trauma | |
US20090017167A1 (en) | Mixture and beverage made therefrom for protecting cellular hydration | |
RO121173B1 (en) | Pharmaceutical composition for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer, and use thereof | |
JP2011509293A (en) | Compositions and methods for increasing muscle mass, strength and functional ability of the elderly | |
US20160346266A1 (en) | Reduction or prevention of alcohol reaction with dietary supplements | |
US20020025310A1 (en) | Compositions and methods for promoting healthy joints | |
US20130004570A1 (en) | Nutritional supplement for use under physiologically stressful conditions | |
JP2006241140A (en) | Nutritive composition for hepatic disease | |
US7628984B2 (en) | Micronutrient formulations for pulmonary and heart health | |
US20180318364A1 (en) | Composition Comprising Lactobacillus Plantarum 2830 (ECGC 13110402) | |
US20220331353A1 (en) | Synergistic compositions and methods to increase vascular nitric oxide to treat endothelial dysfunction and related conditions | |
WO2022182968A1 (en) | Synergistic compositions and methods to increase vascular nitric oxide to treat endothelial dysfunction and related conditions | |
JP5823303B2 (en) | Oral amino acid composition | |
JP2016210720A (en) | Motor function improving agent, respiratory function improving agent, or cognitive ability improving agent | |
JP2007106703A (en) | Preventive and therapeutic composition of angiopathy | |
JP2007330191A (en) | Food suppressing maillard reaction | |
WO2010087150A1 (en) | Gastric acid secretion inhibitor, and potassium channel inhibitor | |
JP2012065607A (en) | Supplement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22760472 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22760472 Country of ref document: EP Kind code of ref document: A1 |